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Abstract 
 O-GlcNAc glycosylation of nuclear and cytosolic proteins is an essential 
post-translational modification implicated in many diseases, from cancer to 
diabetes. Importantly, many important neuronal proteins are also O-GlcNAc 
modified, and aberrant O-GlcNAcylation of these proteins may contribute to the 
pathology of neurodegenerative diseases although these mechanisms have not 
been well defined. Here we investigated the role of O-GlcNAc glycosylation in the 
brain, utilizing both chemistry and molecular biology to study O-GlcNAc 
transferase (OGT), the enzyme that adds the sugar modification. To evaluate the 
role of OGT in adult neurons, we generated a forebrain-specific conditional 
knockout of OGT (OGT cKO) in mice. Although indistinguishable from wild-type 
littermates at birth, after three weeks we observe progressive neurodegeneration 
in OGT cKO mice. Hallmarks of Alzheimer’s disease, including neuronal loss, 
neuroinflammation, behavioral deficits, hyperphosphorylated tau, and amyloid 
beta peptide accumulation, are observed. Furthermore, decreases in OGT 
protein levels were found in human AD brain tissue, suggesting that altered O-
GlcNAcylation likely contributes to neurodegenerative diseases in humans. This 
model is one of a few mouse models that recapitulate AD phenotypes without 
mutating and overexpressing human tau, amyloid precursor protein, or presenilin, 
highlighting the essential role of OGT in neurodegenerative pathways. 
 Given the importance of OGT in the brain, we further investigated the 
regulation of the OGT enzyme by phosphorylation. We found that 
phosphorylation of OGT near its C-terminus reduces its activity in cancer cells, 
vii 
 
and have developed phosphorylation-specific antibodies to aid mechanistic 
studies. Furthermore, mutation of this phosphorylation site on OGT, followed by 
overexpression in neurons was shown to enhance neurite outgrowth, 
demonstrating a functional consequence for this site. Thus phosphorylation of 
OGT inhibits its activity and enhances neurite outgrowth, and current studies aim 
to characterize the signaling pathway that regulates OGT phosphorylation in 
neurons. 
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Chapter 1: Introduction 
1.1 O-GlcNAc Glycosylation 
O-linked N-acetylglucosamine (O-GlcNAc) glycosylation of proteins is an 
increasingly important post-translational modification, implicated in a multitude of 
disease processes. O-GlcNAc glycosylation is ubiquitous, present in all 
metazoans, and is essential for cellular proliferation. The O-GlcNAc transferase 
(OGT) enzyme is responsible for the addition of a single O-GlcNAc sugar to 
serine and threonine residues of proteins, and an O-GlcNAcase (OGA) enzyme 
removes it. Together, these two highly conserved proteins differentially modify 
over one thousand different substrates in a regulated manner, and dynamically in 
response to cellular signaling events. O-GlcNAc modifications have been 
identified on proteins that regulate fundamental cellular processes including 
protein synthesis (1), transcription (2), and cell cycle progression (3, 4).  
Understanding the role of O-GlcNAc in these diverse pathways is of great 
interest, as many disease-relevant pathways are known to be O-GlcNAc 
regulated. Although O-GlcNAc is an essential post-translational modification, it 
was not discovered until the 1980’s, due to its low stoichiometry and chemically 
labile nature. The O-linkage is readily disrupted in typical mass spectrometry 
procedures, which along with its low abundance makes it extremely challenging 
to detect and study. Much work has been done in the past few years to develop 
the tools necessary to study O-GlcNAc, and the most interesting insights into O-
GlcNAc biology have yet to come, as the field matures and the broader scientific 
community begins to appreciate the importance of this unique form of 
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glycosylation. This introductory chapter will establish the key topics associated 
with understanding O-GlcNAc biology, with a focus on its role in the brain.  
1.2 Tools to study O-GlcNAc glycosylation 
 To facilitate the identification and investigation of O-GlcNAcylated 
proteins, there has been a concerted effort in the field to develop strategies to 
selectively label them in complex lysates and in cells. One such method uses a 
chemoenzymatic approach, where O-GlcNAcylated proteins are tagged with a 
galactose sugar containing a bio-orthogonal tag (N-azidoacetylgalactosamine, or 
ketogalactose) (Figure 1.1) (5). This is accomplished with a mutant form of β-1,4-
galactosyltransferase enzyme (Y289L GALT) that specifically adds a galactose 
sugar to terminal O-GlcNAc moieties. This strategy results in stoichiometric 
labeling and allows for the subsequent isolation of O-GlcNAc modified proteins 
which can be analyzed by mass spectrometry to identify amino acid residues 
containing O-GlcNAc modifications. The utility of this method is further extended 
with the addition of a polyethylene glycol (PEG) group to O-GlcNAcylated 
proteins, which results in a shift in apparent molecular weight of a protein of 
interest (6). This allows for the direct quantification of protein O-GlcNAc 
glycosylation, and the use of phosphorylation-specific antibodies further 
elucidates the relationship between O-GlcNAcylation and protein 
phosphorylation. 
 Methods to metabolically label O-GlcNAcylated proteins have also been 
developed, and were shown to label O-GlcNAc-modified proteins in living cells. In 
one study, N-azidoacetylgalactosamine (GalNAz) was shown to be converted to  
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Figure 1.1: Overview of the chemoenzymatic labeling strategy. O-
GlcNAcylated proteins in complex lysates are selectively labeled with a 
mutant GalT enzyme (Y289L) that adds GalNAz (or ketogalactose) to O-
GlcNAc moieties. After reaction of the bio-orthogonal azido group with an 
alkyne tag via 3+2 cycloaddition chemistry, labeled O-GlcNacylated 
proteins can be isolated and subjected to downstream applications. This 
method allows for stoichiometric labeling of O-GlcNAcylated proteins. 
Quantification of O-GlcNAc stoichiometries of specific proteins is 
achieved by appending a polyethylene glycol (PEG) mass tag, which 
results in a shift in apparent molecular weight upon SDS-PAGE. 
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UDP-GalNAz, which was further epimerized to N-azidoacetylglucosamine 
(GlcNAz) (7). This substrate was accepted by OGT in cells to label protein 
substrates. Metabolic labeling allows for the labeling of O-GlcNAcylated proteins 
in live cells, which has the potential to facilitate labeling in whole animals as well 
as labeling in a time resolved manner. However, metabolic labeling is 
substoichiometric, as endogenous UDP-GlcNAc is much more abundant in the 
cell. Thus, labeling of O-GlcNAcylated proteins is incomplete and may suffer from 
significantly lower efficiency.  
 The development of these new strategies to monitor O-GlcNAc 
glycosylation greatly facilitates our ability to investigate the roles of O-GlcNAc in 
the cell. The continued development of tools such as more potent and selective 
inhibitors of OGT or OGA, and model cellular or animal systems to study the 
effects of perturbations in O-GlcNAc levels, will drive future insights. 
1.3 O-GlcNAc Transferase 
Full-length O-GlcNAc transferase contains 1035 amino acids, with an 
apparent molecular weight of 110 kDa. Through complex splicing of its mRNA (8, 
9), OGT exists as three distinct isoforms, which include nuclear/cytoplasmic, 
mitochondrial-targeted, and short forms. These isoforms differ by truncations at 
their N-termini, with mitochondrial and short form OGT having truncations of their 
first 2 and 9 TPR domains, respectively.  
As OGT is responsible for the addition of O-GlcNac onto hundreds of 
different proteins, understanding the regulation of this process represents a 
significant challenge. Whereas over four hundred different genetically encoded 
5 
 
kinases are responsible for phosphorylating specific substrates, a single OGT 
enzyme must modify all substrates selectively and in response to cellular 
signaling events. Current strategies to understand OGT’s substrate specificity 
focus on characterizing its protein-protein interaction domain, the 
tetratricopeptide repeats (TPR) (10). OGT has a series of 11.5 TPR domains at 
its N-terminus that have been shown to mediate its substrate interactions. A 
crystal structure of OGT is shown in Figure 1.2 (11).  
 Each TPR domain is 34-residues long and consists of two anti-parallel α-
helices, which stack in a parallel fashion to form a super-helix that mediates 
binding of different protein partners (12). The sequence of each TPR is unique 
and has the potential to mediate unique interactions. TPR motifs have been 
identified in other proteins, including protein phosphatase 5 (13), anaphase 
promoting complex, and STI1, a co-chaperone protein that forms a complex with 
heat shock proteins (12). It represents a highly conserved protein-protein 
interaction motif, and the presence of different TPR-like structures suggests 
convergent evolution and thus the importance of this structural motif. 
 Several studies have investigated the importance of the TPR domains in 
mediating OGT-substrate interactions. Specifically, nucleoporin 62 (Nup62) (14), 
casein kinase II (CKII) (14), Milton (10, 15), and O-GlcNAcase (16) have all been 
shown to interact with a particular part of OGT’s TPR domains.  For example, 
Milton, a protein responsible for mitochondrial trafficking, was shown to be O-
GlcNAc modified, and to associate with TPRs 2-6 of OGT (10). O-GlcNAcylation 
of Milton was shown to inhibit mitochondrial trafficking in axons which potentially 
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Figure 1.2: Cartoon representation of a crystal structure of OGT. N to 
C-terminus spans blue to red color range. TPR domains are arranged in a 
superhelical orientation and mediate OGT-substrate interactions. The C-
terminal catalytic domain is shown with a casein kinase II peptide bound 
(red).   
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plays a role in the localization of mitochondria to regions of the neuron that 
require increased ATP or have an abundance of glucose. OGA was also shown 
to interact with the N-terminus of OGT, through TPR domains 1-6 (16). A specific 
domain of OGA was also shown to be sufficient for interaction with OGT (aa 336-
548), and this OGT/OGA complex possibly would allow for rapid addition or 
removal of O-GlcNAc in response to stimuli. Indeed, an OGT/OGA complex was 
shown to associate with Aurora B and may regulate cell cycle progression (17). 
Tab1, an activator in TGF-β signaling was shown to interact near the catalytic 
domain of OGT, with TPRs 9-13 (18). Although a handful of these interactions 
have been identified, most OGT-substrate interactions remain undefined. 
 In addition to regulation of OGT activity by substrate interactions, other 
forms of regulation include controlling subcellular localization or post-translational 
modification of the enzyme, by phosphorylation or self O-GlcNAcylation. 
Exploring the role of phosphorylation in OGT regulation is of tremendous interest, 
and the subject of a following chapter. 
As the regulation of OGT and its substrate interactions become more 
defined, improved control over OGT activity towards its substrates will be 
possible by either modulating OGT activation by PTM’s, or targeting specific 
OGT-substrate interactions. Modulation of OGT activity will serve as a powerful 
tool to understand the function of O-GlcNAc on specific substrates, and holds 
great promise for therapeutic development, by targeting O-GlcNAcylation of 
specific substrates.  
 
8 
 
1.4 O-GlcNAcase 
OGA (previously referred to as MGEA5 or NCOAT) is a 916 amino acid 
protein with an apparent molecular weight of 103 kDa. OGA exists in two 
isoforms, a short and long form, that differs by a C-terminal truncation (8, 9). 
OGA is subjected to complex mRNA splicing events and is potentially expressed 
from more than one promoter (19). The enzyme consists of an N terminal 
catalytic domain, and a C-terminal histone acetyltransferase (HAT) domain, and 
contains a caspase 3 cleavage site between the two (20). It is unclear how 
cleavage regulates OGA; however, there is evidence that OGA is catalytically 
active in the absence of its HAT domain (short form) (21). HAT domain of OGA is 
considered to be important for epigenetic regulation, as OGA and OGT exist in a 
complex together at histones. It has been proposed that this complex regulates 
epigenetic factors by dynamically O-GlcNAc glycosylating, or de-glycosylating 
and acetylating histones in response to signaling events (22). 
1.5 O-GlcNAc in metabolism and stress 
The substrate of OGT, UDP-GlcNAc is a metabolic byproduct of 
glycolysis, through the hexosamine biosynthetic pathway (HBP). An estimated 2-
5% of all glucose is diverted to the HBP to produce UDP-GlcNAc. The synthesis 
of the UDP-GlcNAc substrate thus ties together several different metabolic and 
nutrient dependent pathways, including glucose availability, nucleotide 
biosynthesis, and amino acid metabolism. Thus, O-GlcNAc is intimately related 
to cellular metabolism, and affects diseases that involve metabolic dysfunction 
such as cancer (23) and diabetes (24).  
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For example, O-GlcNAc was shown to regulate insulin signaling through 
its modification of IRS1/2, and AKT in 3T3-L1 adipocytes (25). Specifically, 
increased O-GlcNAcylation on IRS1 correlates with reduced binding with PI3K. 
This in turn decreases the activation of AKT in response to insulin signaling, 
which ultimately reduces glucose uptake (Figure 1.3). Furthermore, 
phosphofructokinase-1 (PFK1) was shown to be inhibited by O-GlcNAc 
glycosylation (23). PFK1 glycosylation increases in cancer cells and shunts 
glycolytic flux from glycolysis to the pentose phosphate pathway, providing a 
selective advantage to cancer cells by producing NADH to combat oxidative 
stress and by producing pentose sugars to support nucleic acid biosynthesis 
(Figure 1.3). 
O-GlcNAc has also been studied extensively in the context of the stress 
response, and has been shown to have a protective role. Increasing O-GlcNAc 
levels in cardiomyocytes significantly reduced ER stress-induced cell death by 
attenuating the unfolded protein response (26). Furthermore, O-GlcNAcylation 
was also shown to confer cytoprotection in the heart by attenuating mitochondrial 
permeability transition pore (mPTP) after ischemia injury (27). Specifically, 
calcium overload and reactive oxygen species generation were significantly 
reduced in cardiomyocytes with enhanced O-GlcNAcylation. These studies 
suggest that regulation of OGT and O-GlcNAc is a complex and multifaceted 
system. Thus, this represents a challenging therapeutic target as increased O-
GlcNAcylation in the context of adipocytes contributes to insulin resistance, and 
in cardiomyocytes contributes to cytoprotection. 
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Figure 1.3: O-GlcNAc modification of key proteins regulates disease 
pathways.  O-GlcNAc modification of insulin receptor substrate 1 was 
shown to reduce its binding to PI3K, leading to reduced AKT activation and 
downstream glucose uptake. Furthermore, O-GlcNAc modification of PFK 
inhibits its activity, reducing glycolytic flux. Metabolic products are shunted 
to the pentose phosphate pathway, an alternative metabolic pathway that 
produces Ribose, NADPH, and other molecules essential for cellular 
proliferation and combating oxidative stress. The production of these 
molecules that support cell growth provides a selective growth advantage 
for cancer cells that upregulate their O-GlcNAc modification of PFK. 
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1.6 O-GlcNAc in Neurons  
Although O-GlcNAc is found in all cell types, it is highly enriched in the 
brain. The OGT gene is located in a region of the X chromosome (Xq13) linked to 
Parkinson’s dystonia (28). The gene that encodes OGA is located in a region of 
the chromosome (10q24.1) linked to increased risk of late-onset AD (29). It 
remains to be seen whether mutations or alterations to these chromosome 
regions alter O-GlcNAc cycling in disease; however, the fact that OGT and OGA 
are associated with neurodegeneration-sensitive regions suggests their 
importance in degenerative processes. 
Furthermore, many key neuronal proteins are O-GlcNAc modified, 
including CREB (30), synapsin 1 (31, 32), axonal transport protein Milton (15), 
and AMPA receptor subunit GluA2 (33). Recently, cAMP response element-
binding protein (CREB) was shown to be O-GlcNAc modified. As a key regulator 
of genes responsible for learning and memory in mice, the regulation of CREB 
has been studied extensively in the context of phosphorylation and binding with 
co-activators (34). This recent study identified a new form of CREB regulation via 
O-GlcNAc glycosylation, which was shown to repress CREB activity and affect 
consolidation of short-term memory in mice (30). 
Several studies have suggested that O-GlcNAcylation may play a critical 
role in neurodegenerative processes.  Many neurodegeneration-related proteins 
are O-GlcNAc modified, including amyloid precursor protein (APP) (35), clathrin 
assembly protein AP-180 (36), neurofilament M (37), and tau (38). Although the 
precise roles of the modification in regulating these proteins are not well 
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understood, O-GlcNAcylation of nicastrin, a component of the γ-secretase 
complex that cleaves APP, was shown to decrease γ-secretase activity (39). 
Furthermore, increasing O-GlcNAc levels was shown to increase non-
amyloidogenic processing of APP (40), suggesting a neuroprotective role for O-
GlcNAc in neurons. Similarly, O-GlcNAcylation of tau has been proposed to be 
reciprocally related to its phosphorylation at disease-associated sites (38).  
An increasingly recurrent theme in O-GlcNAc biology is the importance 
maintaining O-GlcNAc levels within an appropriate range. For example, several 
studies have investigated the significance of the modification on synaptic activity 
and long term potentiation/depression. Conflicting results have shown that an 
increase in O-GlcNAc in hippocampal slices increased long-term potentiation 
(LTP) (32), and also increased long-term depression (LTD) (33). Although there 
are differences in the studies (acute (induced LTD) vs. long term (induced LTP) 
treatment with an OGA inhibitor, rat vs. mouse slices, etc), these discrepancies 
illustrate the importance of maintaining a correct balance between OGT and 
OGA activity. Furthermore, characterization of O-GlcNAc levels in Alzheimer’s 
disease (AD) brains has shown a reduction in O-GlcNAc modifications (41). 
However, a recent paper reported increases in O-GlcNAc levels in the brainstem 
of AD patients (42), again providing conflicting results. Collectively, these findings 
suggest that targeting OGT or OGA with general inhibitors to treat diseases may 
lead to unwanted consequences, and motivates the development of 
complementary strategies to carefully spatially control OGT and OGA activity.  
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1.7 Challenges to Studying O-GlcNAc Glycosylation 
 As previously stated, O-GlcNAc glycosylation has been challenging to 
study for a variety of reasons. First, the modification is substoichiometric and 
chemically labile, which makes detection quite difficult (6, 43, 44). As a result, 
new methods and strategies for reliably detecting O-GlcNAc modifications have 
been recently developed (5, 7, 44). Another significant challenge to studying O-
GlcNAc modifications is that single OGT and OGA enzymes are responsible for 
cycling the modification on and off hundreds of different substrates (20, 45). 
Thus, studies with small-molecule inhibitors or RNAi that are typically employed 
to study protein function provide results that are difficult to interpret. Inhibition of 
OGT activity for instance, generally decreases O-GlcNAc modification of over 
one thousand substrates all at once, and convolutes phenotypic analysis. 
Furthermore, as O-GlcNAc modification is required for cell-cycle 
progression, complete knockout of OGT in dividing cells is not possible (3, 4). 
Indeed, our studies have shown that knockdown of OGT with RNAi is often 
incomplete, and more importantly, selected against after several passages 
because of the selective growth advantage conferred by OGT (46). Work in the 
following sections describes our efforts to study O-GlcNAc glycosylation by 
utilizing conditional knockout strategies, characterizing the regulation of the OGT 
enzyme, and developing better tools to manipulate O-GlcNAc in vitro. Through 
this work, some of these challenges have been addressed while others await 
ongoing and future studies. 
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1.8 Conclusions 
After its discovery over thirty years ago, O-GlcNAc glycosylation has 
proven to be a tremendously interesting regulator of cellular biology. Significant 
challenges to studying the modification due to its low abundance and chemically 
labile O-linkage have been addressed through the development of new 
strategies. By specifically tagging O-GlcNAc modifications, modified proteins can 
be enriched and facilitate downstream molecular biology studies. Furthermore, 
advancements in mass spectrometry technologies have greatly improved our 
ability to identify sites of O-GlcNAcylation and have facilitated functional studies 
of O-GlcNAc-modified proteins. 
Both OGT and OGA are complex proteins responsible for acting on many 
hundreds of proteins. As a result they require extensive regulation that is only 
beginning to be understood. As more proteins involved in fundamental cellular 
and disease processes are found to contain O-GlcNAc modifications, it will 
become increasingly important to understand the regulation of the OGT and OGA 
enzymes, and to modulate their activity. 
Developing better inhibitors of O-GlcNAc glycosylation, possibly at the 
level of substrate-OGT interactions may provide viable strategies for targeted 
disruption of O-GlcNAcylation. Studies that currently seek to modulate OGT 
activity often rely on small molecule OGT active-site inhibitors, many of which 
suffer from poor specificity and significant off-target effects. Furthermore, specific 
and potent inhibition of OGT, even when possible, leads to a global decrease of 
all O-GlcNAc modified proteins, complicating phenotypic or mechanistic analysis. 
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Given the modular nature of TPR domains, it is expected that specific inactivation 
of one or a few TPR domains at a time would provide significantly improved 
control over OGT activity by inhibiting small sets of substrates at a time. Both 
understanding O-GlcNAc biology and finding ways to augment the modification 
will be important areas of focus for future therapeutic development.  
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Chapter 2: Generation and characterization of a conditional 
forebrain-specific OGT knockout to understand the role of O-
GlcNAc in the brain 
2.1 Introduction 
Alzheimer’s disease (AD) is the sixth leading cause of death in the United 
States, and is characterized by the accumulation of extracellular senile plaques, 
intracellular neurofibrillary tangles, and progressive cognitive decline. There are 
currently no effective treatments for AD and current efforts to combat disease 
progression focus on reducing amyloid beta peptide and hyperphosphorylated 
tau protein levels. It is unclear how AD pathology proceeds in humans, but 
mouse models have provided significant insight. Through these studies, key 
disease-relevant pathways have been identified, including protein homeostasis, 
cell-cycle progression, and metabolism. It remains to be seen whether these 
diverse pathways are related and how they contribute to neurodegeneration. 
O-GlcNAc glycosylation is a dynamic, inducible post-translational 
modification that regulates many critical biological processes, including insulin 
signaling (1), transcription (2), cell cycle regulation (3), stress responses (4)and 
proteosomal degradation (5-7).   In mammalian cells, a single O-GlcNAc 
transferase (OGT) enzyme catalyzes addition of the sugar N-acetylglucosamine 
to serine or threonine residues of proteins (8), and a single glycosidase enzyme, 
O-GlcNAcase (OGA) (9), removes it. Together, these enzymes cycle the 
modification on and off proteins in response to nutrient availability, various 
cellular stresses, neuronal depolarization, and other stimuli.  
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Emerging evidence suggests that O-GlcNAcylation plays essential roles in 
the brain and may contribute to the regulation of learning and memory. For 
example, the transcription factor cAMP-response element binding protein 
(CREB) is highly O-GlcNAcylated in neurons and its glycosylation is dynamically 
induced by neuronal activity (10). CREB glycosylation at a single site disrupts its 
interaction with the coactivator TORC and thereby represses both basal and 
inducible CREB-dependent transcription. Notably, blocking glycosylation at this 
site leads to accelerated formation of long-term fear memories in mice 
suggesting that O-GlcNAc can contribute to higher order brain functions. The O-
GlcNAc modification has also been identified on numerous synaptic proteins, 
including synapsin I (11), the axonal transport protein Milton (12), and the AMPA 
receptor subunit GluA2 (13). Glycosylation of synapsin I at Thr87 affects its 
targeting to synaptic vesicles, and overexpression of a glycosylation-deficient 
synapsin mutant increases the density of synaptic vesicle clusters along axons 
(14). On the other hand, induced O-GlcNAcylation of Milton significantly reduces 
mitochondrial motility in axons (12). Local increases in glucose levels or neuronal 
activity, both of which are known to upregulate OGT activity, are thought to 
dynamically increase Milton O-GlcNAcylation, thereby increasing the local 
concentration of mitochondria. This potentially serves as a mechanism by which 
mitochondria are targeted to regions of abundant glucose, or regions of high 
neuronal activity to efficiently produce ATP where it is needed. Global increases 
in O-GlcNAcylation have also been shown modulate long-term depression (LTD) 
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in rat hippocampal slices through GluA2 (13), although the exact mechanisms 
are unknown.   
In addition to its effects on fundamental neuronal processes, O-
GlcNAcylation may play a critical role in neurodegenerative diseases such as 
Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Huntington’s 
disease.  Several key proteins involved in neurodegeneration are O-GlcNAc 
modified, including amyloid precursor protein (APP) (15), clathrin assembly 
protein AP-180 (16), neurofilament M (17), and tau (18). Although the precise 
roles of the modification are not well understood, O-GlcNAcylation appears to be 
reciprocally related to phosphorylation on neurofilament M and tau at disease-
associated sites (18). Decreased O-GlcNAcylated neurofilament M (NFM) was 
associated with increased phosphorylation of NFM in the spinal cord of a 
transgenic rat model of ALS (10). Similarly, increased tau O-GlcNAcylation at 
serine-400 led to a decrease in tau phosphorylation at serine-404 in vitro (19), 
while increasing global O-GlcNAcylation reduced tau phosphorylation at 
threonine-212, threonine-217, serine-396, and serine-422 in mouse brain slices 
(20). Consistent with a neuroprotective role for O-GlcNAc, glycosylation of 
nicastrin, a component of the γ-secretase complex that cleaves APP, was shown 
to decrease γ-secretase activity (21), and globally increasing O-GlcNAc levels 
enhanced the non-amyloidogenic processing of APP (22). In addition, treatment 
of certain AD mouse models (5XFAD, JNPL3, and Tau.P301L) with small 
molecule inhibitors of OGA attenuated amyloid-β deposition (21), tau 
phosphorylation (23), motor deficits (24), and memory impairment (21).  
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On the other hand, studies show that decreasing O-GlcNAc levels can 
also rescue certain neurodegenerative phenotypes, which suggests that a 
delicate homeostatic balance in O-GlcNAc levels may be required.  For example, 
elevating O-GlcNAc glycosylation levels inhibited the 26S proteasome (7) and 
autophagic flux (25), which may impair the degradation of toxic protein 
aggregates. Indeed, a recent report demonstrated that in C. elegans, genetic 
deletion of OGT reduced the ubiquitinylated protein load and altered autophagic 
flux, which alleviated neurodegenerative phenotypes in transgenic models of 
tauopathy, amyloid β-peptide, and polyglutamine expansion (26). In addition, 
global reduction in O-GlcNAcylation increased the survival of Neuro2A cells 
expressing mutant huntingtin I (mHtt) by increasing autophagic flux (27). Thus, 
O-GlcNAc glycosylation appears to play a complex role in neurodegeneration, 
and whether decreased O-GlcNAcylation contributes to neuroprotection or 
neurodegeneration is presently unclear. Moreover, it is unclear whether aberrant 
O-GlcNAc signaling merely correlates with neurodegenerative phenotypes or 
whether it can cause neurodegeneration in vivo. 
OGT is ubiquitously expressed and essential for cell cycle progression 
and proliferation  (28, 29), complicating efforts to study its function.  For instance, 
deletion of OGT in multiple mammalian cell types leads to cell death (28, 29). 
Previous efforts to generate a constitutive OGT knockout mouse resulted in 
embryonic lethality, and a later study that generated a brain-specific OGT 
knockout mouse produced early postnatal lethality (28, 29).  This conditional 
knockout was accomplished by using a Cre-loxP system, in which exon 1 of OGT 
27 
 
was flanked by two loxP sequences (floxed). LoxP sequences consist of 34 base 
pairs that are recognized by the Cre recombinase enzyme (30). Upon binding 
loxP sequences, Cre recombinase catalyzes the excision of the stretch of DNA 
between the two loxP sites. Thus, by restricting expression of Cre recombinase 
with a brain-specific promoter (synapsin), OGT knockout was limited to the brain 
(31). Despite the early postnatal lethal phenotype, these mice displayed 
increases in phosphorylated tau and provided initial evidence that OGT may play 
an important role in degenerative processes (31).  
In this study, we generated a forebrain-specific conditional OGT knockout 
mouse to assess the effects of global loss of O-GlcNAcylation on learning, 
memory, and neurodegeneration in adult mice. The mice were healthy at birth, 
but starting at 2 months, they developed signs of progressive neurodegeneration, 
including loss of neurons, neuroinflammation, memory deficits, and increased 
hyperphosphorylated tau and pathogenic amyloid β-peptide. Microarray analysis 
of gene expression revealed an upregulation of networks associated with 
inflammation and cell cycle arrest, suggesting possible roles for gliosis and 
aberrant cell cycle regulation in O-GlcNAc-dependent neurodegeneration. 
Finally, our analysis of cortical tissue from human AD patients indicated a 
significant reduction in OGT protein levels compared to healthy individuals, 
suggesting that altered O-GlcNAcylation likely contributes to neurodegenerative 
diseases in humans. Together, our studies directly link reduced O-GlcNAcylation 
to the induction of several neurodegenerative phenotypes, suggesting a viable 
strategy for the amelioration of such diseases. 
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2.2 Results 
2.2.1 Generation of a conditional OGT knockout mouse 
In order to circumvent the requirement for OGT during neuronal 
development, we restricted knockout to the forebrain and beginning after birth. 
We utilized an αCaMKII promoter driven Cre recombinase mouse (αCamKII –
Cre) that expresses Cre recombinase in the forebrain beginning after postnatal 
day 14 (32). Validation of the expression profile of αCamKII -Cre was performed 
by crossing this line with a floxed YFP mouse and characteristic forebrain 
specific expression of YFP was confirmed (Figure 2.1). We then crossed the 
αCamKII -Cre mouse with a previously characterized floxed OGT (OGTfl) mouse 
(28), and obtained a conditional knockout of OGT (OGT cKO). OGT cKO mice 
did not breed and necessitated maintaining OGTfl and αCaMKII -CRE mouse 
lines separately. By breeding homozygous OGTfl females (OGTfl-/-) with 
heterozygous αCaMKII-CRE males (CamKIICRE+/-) we were able to produce 
OGT cKO mice along with wild-type littermates (Figure 2.2). Additionally, only 
male mice were considered in this study due to random X inactivation of the OGT 
gene in females, which would complicate phenotypic analysis. Genotyping was 
conducted with previously established protocols for CRE and OGTfl genes and 
OGT cKO mice were produced at the expected frequencies and were 
indistinguishable from wild type littermates at birth. 
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Figure 2.1: CaMKII-CRE expression is forebrain specific. CaMKII-CRE mice were crossed with 
floxed ROSA YFP mice to characterize the expression pattern of CaMKII-CRE. 6 month old 
animals were stained for YFP (green) and imaged with a NeuN (red) counterstain, and show 
largely forebrain specific expression with no signal in the cerebellum, in a pattern similar to 
previous reports.  
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Figure 2.2: Breeding strategy to generate OGT cKO mice. CaMKII-CRE mice 
were bred separately from the floxed OGT (OGTfl) mouse line, because OGT 
cKO mice did not breed. Homozygous OGTfl females were bred with 
heterozygous CaMKII-CRE studs to produce male offspring that were OGTfl/Y, 
CRE wt/- or CRE wt/wt. Thus, OGT cKO mice were generated with wild type 
littermates for control studies. Female offspring were culled to avoid any 
complications with phenotypic analysis due to random X-inactivation. – denotes 
carrier, + denotes wild type. 
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2.2.2 Loss of O-GlcNAcylation is accompanied by progressive 
neuronal loss 
OGT cKO mice were indistinguishable from their WT littermates until 7 
weeks of age, after which they began to show a significant reduction in weight 
(10.9% reduction at 7 weeks; 32% at 16 weeks; Figure 2.3A, B). Along with this 
weight reduction, the brains of OGT cKO mice were significantly smaller overall, 
by 4 months (Figure 2.3C). We observed global changes in brain morphology by 
Nissl staining, which revealed a striking loss of neurons in the hippocampus by 
16 weeks of age and a 56% reduction in cortical thickness at 6 months (Figure 
2.3C, D). Although OGT cKO mice did not have decreased survival rates before 
6 months, they exhibited excessive grooming by 5 months of age, which resulted 
in hair-loss, skin lesions and necessitated culling of the mice after 7 months.  
Golgi stain was used to examine the morphology of hippocampal and 
cortical neurons. At 6 months, hippocampal neurons showed dramatic reductions 
in dendritic arborization, and pyramidal cortical neurons showed significant loss 
of dendrites (Figure 2.4). Reduction in brain volume was more accurately 
quantified by MRI and tensor-based morphometry, and demonstrated a 20% 
reduction in brain volume (Figure 2.5). Regions of decreased brain volume are 
denoted with red shading, whereas regions with increases are denoted with blue 
shading. Significant decreases in hippocampal and cortical volume are observed, 
as well as a reduction in the volume of thalamus/midbrain regions. Some 
decreases are also observed in the cerebellar region, but these changes are not 
seen in histological experiments.  
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Figure 2.3: OGT cKO mice display reduced weight and brain size beginning at 2 months. (A) 
OGT cKO mice were significantly smaller by 6 months of age. (B) A decrease in weight is observed in 
OGT cKO mice beginning at 7 weeks. (C) Overall brain size and cortical thickness are reduced at 4 
and 6 months in OGT cKO mice. (D) Nissl stain shows shrinking cortical and hippocampal structures 
in OGT cKO mice. *P<0.005, **-P<0.0005. 
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Figure 2.4: Golgi stain reveals dramatic degeneration of neuronal 
processes. Neurons in the hippocampus and cortex have fewer processes in 
6 month old cKO mice. In addition, cortical and hippocampal structures are 
significantly reduced in size. 
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Figure 2.5: MRI analysis identifies reduction in  cortical, 
hippocampal, and thalamic brain volume. Tensor-based 
morphometry analysis of MRI scans shows regions of cKO 
brains that are significantly reduced in size compared to wild-
type controls (red). Regions affected include the cortex, 
hippocampus, and part of the thalamus.  
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Immunohistochemistry using a pan-specific anti-O-GlcNAc antibody (RL2) 
confirmed progressive loss of O-GlcNAcylation in the cortex and hippocampus 
(Figure 2.6A). Beginning at 1 month, 5-10% of CA1, dentate gyrus (DG), and 
cortical neurons lacked O-GlcNAc, and by 2-4 months, the loss of O-GlcNAc 
peaked in approximately 40% of the neurons (Figure 2.6B).  By 6 months, fewer 
O-GlcNAc-depleted neurons remained. The pattern of O-GlcNAc loss was similar 
in the cortex, with knockout beginning at 2 months (Figure 2.7A, B). The 
specificity of the anti-O-GlcNAc antibody was confirmed by competition 
experiments using free GlcNAc sugar (Figure 2.8A). As an internal control, we 
measured OGT immunoreactivity in the cerebellum (which lacks αCaMKII 
expression) and detected levels comparable to those of WT mice (Figure 2.8B). 
Western analysis confirmed loss of O-GlcNAc modified proteins in the cortex, 
hippocampus, but not cerebellum (Figure 2.9A). Furthermore, OGT and OGA 
levels were both significantly reduced in the hippocampus of OGT cKO mice 
(Figure 2.9B, C).  
OGT antibodies (DM17, AL25) were used to confirm the progressive loss 
of OGT in the cortex and hippocampus, and agree with the results obtained with 
RL2 immunohistochemistry (Figure 2.10). OGT protein levels are significantly 
reduced in the hippocampus at 1 month, consistent with the 5-12% reduction in 
RL2-positive neurons at 1 month (Figure 2.6B). This result suggests that loss of 
OGT begins around 1 month of age, while significant reduction in RL2-positive 
neurons is observed at 2 months. RL2 staining was much more robust than OGT  
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Figure 2.6: Characterization of OGT knockout, neuronal loss, and degeneration. (A) 
Knockout of OGT as well as neuronal loss occurs in the CA1, dentate gyrus, and cortex. (B) O-
GlcNAc-negative (knockout) neurons in OGT cKO mice. (C) Quantification of neuronal loss in 
OGT cKO mice Scale bar = 50um. 
1 WT 
1 cKO 
2 WT 
2 cKO 
4 WT 
4 cKO 
6 WT 
6 cKO 
0 
10 
20 
30 
40 
50 
CA1 DG 
N
eu
ro
ns
 /
 1
00
um
2  
O
-G
lc
N
A
c 
N
eg
at
iv
e 
N
eu
ro
ns
 (%
) 
CA1 DG 0 
10 
20 
30 
40 
50 1 cKO 
2 cKO 
4 cKO 
6 cKO 
N
euN
 
O
-G
lcN
Ac 
37 
 
   
0 
10 
20 
30 
40 
50 
Cortex 
0 
10 
20 
30 
40 
50 
O
-G
lc
N
A
c 
N
eg
at
iv
e 
N
eu
ro
ns
 (%
) 
Cortex 
1 WT 
1 cKO 
2 WT 
2 cKO 
4 WT 
4 cKO 
6 WT 
6 cKO 
1 cKO 
2 cKO 
4 cKO 
6 cKO 
N
eu
ro
ns
 /
 1
00
um
2  
Figure 2.7: Characterization of OGT knockout, neuronal loss, and degeneration in the 
cortex. (A) Knockout of OGT as well as neuronal loss occurs in cortex. (B) O-GlcNAc-negative 
(knockout) neurons in OGT cKO mice. (C) Quantification of neuronal loss in OGT cKO mice. 
Scale bar = 50um. 
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Figure 2.8: O-GlcNAc antibody is specific and OGT protein is present in the 
cerebellum. (A) O-GlcNAc antibody (RL2) signal is eliminated by competition with the 
addition of free GlcNAc sugar (1M) during incubation with primary antibody . (B) OGT 
(AL25) protein is present in purkinge neurons of the cerebellum (green) in 2 month OGT 
cKO mice, demonstrating forebrain-specific knockout of OGT. Neurons are stained with 
NeuN (red). Scale bar = 50um. 
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Figure 2.9: Conditional knockout of OGT in the forebrain. (A) O-
GlcNAc-modified proteins (RL-2) are significantly decreased in OGT cKO 
mouse hippocampi and cortex but not cerebellum at 2 months. (B) OGT 
protein levels are significantly reduced in cKO mice at 2 months. (C) OGA 
protein levels are significantly reduced by 2 months. *-P<0.05, ***-
P<0.0005. 
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Figure 2.10 : Loss of OGT Begins at 1 Month and Continues to 6 Months. OGT antibody (AL-
25, green) was used to stain for OGT in the cortex, CA1, and dentage gyrus of OGT cKO mice. 
NeuN (red) was used to stain neuronal nuclei, and DAPI (blue) was used to stain DNA. Loss of 
OGT signal begins at 1 month but by 4 months most OGT-null neurons are absent. Progressive 
loss of neurons is also apparent at 4 and 6 months. 
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staining, and thus RL2 immunohistochemistry was used to quantify the time 
course of OGT knockout. 
OGT cKO mice displayed a profound and progressive loss of neurons by 2 
months. Quantification of CA1 neurons by NeuN staining revealed a 19.4% 
reduction in neuronal number at 2 months (Figure 2.6C) and a 23.1% reduction 
in the dentate gyrus.  At 4 months, there was a 52.6% reduction in neuronal 
number, and at 6 months, the value progressed to 60.0%. A similar trend in 
neuronal loss was observed in the DG region of the hippocampus (23.1%, 70.7% 
and 82.6%, at 2, 4, and 6 months, respectively; Figure 2.6C). The cortex showed 
no appreciable change in neuronal density (Figure 2.7C), however the significant 
reduction in cortical thickness illustrates the overall loss of cortical neurons 
(Figure 2.3C). 
Neuronal loss was also quantified by Nissl and TUNEL staining. At 2 
months, Nissl stained slices showed a significant amount of condensed pyknotic 
nuclei, which are indicative of cells undergoing apoptosis (Figure 2.11A). 
Furthermore, 56.6% (16.7 neurons / 100 µm2) of DG neurons were positive for 
TUNEL labeling (Figure 2.11B), confirming extensive apoptosis in the 
hippocampus of OGT cKO mice. To identify degenerating neurons, we used 
Fluorojade-C (FJC), which revealed that 33.2% (19.4 neurons /100 µm2) of DG 
neurons were FJC-positive (Figure 2.11C). Interestingly, while most FJC-positive 
neurons lacked O-GlcNAcylation, some neurons were positive for both FJC and 
O-GlcNAc (Figure 2.11C, arrowheads). This suggests that loss of OGT can lead  
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to degeneration of neighboring OGT-positive neurons. In contrast, no TUNEL or 
FJC labeling of DG neurons from WT mice was observed. 
2.2.3 Changes in anxiety and deficits in fear conditioning accompany 
OGT cKO 
To assess the functional consequences of conditional OGT knockout, we 
evaluated OGT cKO mice in a series of behavioral tasks. Initially, we observed 
that OGT cKO mice exhibit deficits in nest making abilities, as well as an 
excessive grooming phenotype at 4 months, both of which have been observed 
in neurodegenerative mouse models of OCD and schizophrenia (33, 34). To 
assess basic motor ability, we used a rotarod exercise and determined that OGT 
cKO mice retain normal motor function, at both 2 and 4 months compared to 
wild-type littermates (Figure 2.12A). Subsequently, an open field test was used to 
determine basal anxiety levels. OGT cKO mice demonstrated significant 
increases in anxiety, with a 27.8 and 95.3% decrease at 2 and 4 months, 
respectively, in the duration spent exploring the exposed quadrant of an open 
field (Figure 2.12B). Additionally OGT cKO mice exhibited a 45.4% decrease in 
total distance traveled during the open field task (Figure 2.12B), suggesting an 
increase in basal anxiety through reduced exploration of an exposed 
environment.  
We used a fear conditioning task to evaluate changes in the ability of OGT 
cKO mice to learn new associations. OGT cKO mice displayed a small but 
significant 10.9% deficit in cued-auditory (amygdala dependent) freezing at 2 
months, but no change in contextual (hippocampus dependent) freezing (Figure  
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Figure 2.12: OGT cKO mice have normal locomotor function but show increases in 
anxiety. (A) Mice were subjected to a rotarod test, and cKO mice show no deficits in locomotion. 
(B) OGT cKO mice show increased anxiety in an open field test with significant reductions in 
time spent in the middle (exposed) quadrant of the box as well as in total distance traveled, as 
illustrated by a representative trace of movement. *-P<0.05, **-P<0.005. n= 12 for each 
genotype. 
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2.13). By 4 months, however, significant deficits in both cued (31.1%) and 
contextual (24.4%) fear-related freezing were observed. These results are 
consistent with the observed neurodegeneration by histology, and demonstrate 
significant progression of memory impairments in OGT cKO mice. 
2.2.4 Deficits in additional memory tests suggest short-term memory 
impairments 
 The Y-maze was used to assess short-term memory, as mice with good 
short-term memory are able to recall which arm of the maze they were previously 
exploring, and will alternate their arm entries. OGT cKO mice showed no 
significant changes in alternation of arm entries compared to wild-type mice 
(Figure 2.14). Furthermore, they explored the maze with a similar number of arm 
entries when compared to wild-type mice, which eliminates complicating factors 
such as a reduced activity or increased anxiety.  
 A place preference test was the performed to assess whether the mice are 
able to recall the context or location of a particular object. Mice were allowed to 
explore an environment containing two objects, and then removed from the 
environment. While absent, one of the objects was relocated. Mice were then 
replaced in the environment, and exploration of each object was quantified. If the 
mice recalled the context of the objects, they would generally identify that one 
object had been moved, and would have a preference for exploring that relocated 
object. OGT cKO mice showed a small decrease in place preference, but 
because the preference of wild type mice was quite low, this experiment was not 
pursued further (Figure 2.15). Thus it is possible that OGT cKO mice have  
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Figure 2.13: Behavioral changes in OGT cKO mice include impaired fear-related 
related learning. Significant deficits in cued (amygdala-dependent) fear conditioning 
is observed at 2 months in OGT cKO mice, and deficits in both cued (amygdala-
dependent) and contextual (hippocampus-dependent) are observed by 4 months of 
age (C). *-P<0.05, **-P<0.005. n=12 for each genotype. 
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cKO mice. Total arm entries were counted to evaluate changes in exploratory 
activity and no changes were observed. Entries into each arm of the Y-maze were 
noted and used to evaluate short-term memory, by quantifying the percentage of 
alternating arm entries. Deficits in short-term memory would present as decreased 
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have no preference for entering a less recently explored arm. N=8 for each genotype. 
4 month time point. 
4M WT 4M cKO 
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Figure 2.15: Place preference study suggests a deficit in short-term memory 
and identifies a possible hyperactive phenotype. Preference for exploring an 
object that was moved between an initial and final exploration period was assessed. 
Animals that recall the original location of the moved object would preferentially 
explore the moved object. OGT WT mice seemed to have a preference for exploring 
the moved object, and OGT cKO mice appeared to have no preference, but more 
replicates are needed as the changes are not significant. Furthermore, total distance 
traveled while exploring the objects was quantified, and demonstrates increased 
activity of OGT cKO mice as they explore the objects. This increased exploration is 
interesting to consider in light of the increased anxiety observed in the open field test, 
and may suggest a hyperactive phenotype. N=4 for each genotype, 2 month time 
point. 
4M WT 4M cKO 
Initial  Final Initial  Final 
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impaired short-term memory, but more replicates are required to draw 
meaningful conclusions. Interestingly, OGT cKO mice displayed a significant 
increase in total distance traveled while exploring the environment, compared to 
wild-type mice. This was in stark contrast to the open field test, where OGT cKO 
mice were shown to have increased anxiety and lower overall distance traveled. 
OGT cKO mice not only traveled longer distances to explore each object more 
thoroughly, they routinely made contact with the objects and were much less 
inhibited in their exploration of the object compared to wild-type mice (Figure 
2.15).  
2.2.5 Microarray analysis of OGT cKO mRNA suggests changes in 
immune and cell cycle related genes 
OGT modifies and regulates many different intracellular substrates 
including many different transcription factors. We sought to better understand the 
specific transcriptional changes in OGT cKO mice using microarray technology. 
Messenger RNA from the hippocampi of 3-week and 2-month old cKO mice and 
their wild-type littermates were isolated and run on microarray chips. At 3 weeks 
of age, there were only 10 differentially-expressed genes in the hippocampi when 
comparing OGT cKO mice to wild-type mice (Table 2.1).  In contrast, at two 
months, there were over 900 differentially-expressed genes in cKO hippocampus 
compared to their wild-type littermates (Table 2.2).  Immune response genes 
expressed by microglia and astrocytes were among the most highly upregulated 
genes (Table 2.2).  Markers such as GFAP and C1q were significantly 
upregulated and confirmed by qRT-PCR. Furthermore, many of these genes  
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Table 2.1: Differentially Expressed Genes in OGT cKO Mice at 3 weeks. Few genes are differentially 
expressed at 3 weeks of age, when conditional knockout of OGT is just beginning. Elizabeth Jensen 
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Table 2.2: Differentially Expressed Genes in OGT cKO Mice at 8 weeks. Immune response related 
genes are upregulated in our flOGT cKO mouse as well as in several mouse models of AD.  In all of 
these mouse models of AD, the mice express a familial Alzheimer’s disease mutant amyloid precursor 
protein as well as a familial Alzheimer’s disease mutant presenilin-1. The upregulation of immune 
response genes is observed at 2 months while the other mouse models observe upregulation at 12 or 18 
months of age.  The p-values are Bonferroni corrected p-values.  Elizabeth Jensen 
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were found to also be upregulated in other established models of AD (Table 2.2). 
Interestingly, these transcriptional changes are observed at 2 months of age, 
while similar immune response gene upregulation is observed in other mouse 
models at 12 or 18 months of age (35-37).  
In order to determine other networks of genes that were deregulated in the 
OGT cKO, a weighted gene co-expression network analysis (WGCNA) was 
performed on the microarray data (38, 39). Our WGCNA identified two gene 
modules (green and magenta), which were significantly correlated with Cre 
expression and OGT knock-out (Figure 2.16). Using DAVID and gene ontology 
analysis, the green module was shown to be enriched with genes involved with 
immune response (p < 3.4 x 10-4) (40). VisANT was used to visualize the green 
module network (41-43). 
Interestingly, the magenta module was enriched for genes involved with 
cell cycle arrest (p < 3.75 x 10-5) (Figure 2.16). The WGCNA data implicates cell 
cycle deregulation as an important mechanism that underlies the physiological 
and behavioral changes observed in the OGT cKO mice.   
To explore this further, we probed our model for changes in CDK5, a key 
regulator of neuronal cell cycle. CDK5 protein levels were decreased by 26% in 2 
month old cKO mice by western blot, and IHC staining showed a significant 
decrease in CDK5 levels in O-GlcNAc null neurons in the hippocampus (Figure 
2.17A, B). Interestingly, CDK5 was also found to be O-GlcNAc modified in mouse 
brain after chemoenzymatic labeling (Figure 2.17C). CDK5 has many functions in 
addition to suppressing cell cycle progression, including phosphorylation of tau  
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A.  B.  
C.  D.  
Figure 2.16: WGCNA Results indicate increases in immune and cell cycle arrest genes.  A. 
Cre expression and OGT knock-out is significantly and highly correlated with the green module 
membership (cor = 0.71, p = 3.8 x 10
-28
).  B. Displayed is the Visant green module network 
(cutoff > 0.1).  Gene ontology analysis reveals that these genes are overwhelmingly related to 
immune response (enrichment p < 3.75 x 10
-5
).  C. Cre expression is highly correlated with the 
magenta module (cor = 0.77, p = 1.2 x 10
-18
).  D. Shown here is the Visant green module 
network (cutoff > 0.1). Gene ontology analysis reveals that these genes are overwhelmingly 
related to immune response (enrichment p < 3.4 x 10
-4
). 
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O-GlcNAc 
Figure 2.17: CDK5 is decreased in O-GlcNAc negative neurons and is O-GlcNAc 
glycosylated.  (A) Immunohistochemistry shows O-GlcNAc negative neurons have decreased 
CDK5 staining (A, arrowheads) in the hippocampus at 2 months. OGT cKO mice show a 26% 
decrease in global CDK5 levels by western blot. (C) CDK5 is O-GlcNAc modified in mouse brains 
after chemoenzymatic labeling with biotin and streptavidin pull down (C). Scale bar = 50um. 
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and regulating MEK1 signaling. Thus it is possible that the reduction in CDK5 
levels in OGT cKO mice could contribute to our observed neurodegeneration. 
2.2.6 OGT cKO recapitulates AD phenotypes including 
neuroinflammation, phosphorylated tau, and increases in amyloid β 
peptide 
As O-GlcNAc modifications have been shown to affect several AD-related 
proteins, including tau and APP, we explored whether our mouse displayed 
changes in these hallmarks of neurodegeneration. We began by evaluating 
changes in microglia and astrocytes, as both play an important role in supporting 
neuronal health. Beginning at 2 months, a 6.48-fold increase in astrocyte and 
14.9-fold increase in microglia markers was observed in the hippocampus of 
OGT cKO mice (Figure 2.18). This striking gliosis spreads to the cortex by 6 
months and persisted throughout the life of the animal. 
O-GlcNAc modification of tau was shown to reduce tau aggregation and 
phosphorylation in other AD mouse models (44). Using immunohistochemistry, 
we evaluated several epitopes of phosphorylated tau that have been shown to be 
characteristic of paired-helical filamentous (PHF) tau oligomers, which aggregate 
to form neurofibrillary tangles (NFTs) in AD (45, 46). We observed an increase in 
phosphorylation of tau at T205 (1.8 fold), S396 (2.9 fold), and T231 (1.4 fold) 
beginning at 2 months in the mossy fibers and cell bodies of neurons in the 
dentate gyrus in a pattern similar to NFTs (Figure 2.19, arrowheads). These 
results were confirmed by western blot analysis, using additional tau antibodies 
AT8 (T202/T205, 1.4 fold) and AT180 (T231, 1.4 fold) (Figure 2.20). A 3D  
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Figure 2.18: OGT cKO mice exhibit Gliosis. Microglia and astrocyte proliferation in 
CA1 region of the hippocampus ***-P<0.0005. Scale bar = 50um. 
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Figure 2.19: OGT cKO mice accumulate hyperphosphorylated tau. Increases in several 
pathological phosphorylation sites on tau and can be seen accumulating in both soma and 
axons of dentate gyrus neuron by immunohistochemistry (A, arrowheads). **-P<0.005, ***-
P<0.0005. Scale bar = 50um. 
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WB: AT8 (p202/205) 
WB: AT180 (p231) 
WB: Tau 5 
Figure 2.20: OGT cKO mice accumulate hyperphosphorylated tau. (western blot) 
Increases in several pathological phosphorylation sites on tau by western blot at 6 months. 
*-P<0.05, **-P<0.005. 
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rendering of hyperphosphorylated tau in the mossy fibers of the dentate gyrus 
illustrates the accumulation of pathogenic tau (Figure 2.21).  
As hyperphosphorylation of tau has been shown to affect tau solubility (47, 
48), we isolated tau from OGT cKO mice and assessed whether changes in 
solubility were detectable compared to wild-type mice. Lysates were solubilized 
in sarkosyl detergent, and evaluated by ultracentrifugation. Total tau and 
phospho-S396 tau were probed on a western blot, and showed no significant 
changes in solubility between OGT cKO and wild-type mice (Figure 2.22). A 
majority of tau was soluble in detergent-free lysis buffer, and there was no 
change in the percentage of tau that was insoluble in sarkosyl.  
Tau is expressed as different isoforms, and changes in isoform expression 
have been previously associated with diseased states (49-51). Tau can be 
expressed with 3 or 4 repeat domains depending on splicing events, and these 
species have different apparent molecular weights. We initially observed that 
OGT cKO mouse tau would often display an increase in the ‘upper band’ 
compared to wild-type mouse tau, and we hypothesized that this could be due to 
changes in tau isoform expression (Figure 2.23, bold arrow). Tau 
phosphorylation has previously been shown to affect tau migration on SDS-
PAGE, and we sought to identify the cause of the changes in the abundance of 
the ‘upper band’ from OGT cKO mice. Protein phosphatase lambda (PPL) was 
added to lysates, and samples were compared to untreated lysates. After PPL 
treatment, changes in apparent molecular weight between OGT cKO and wild- 
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Figure 2.21: 3D rendering of hyperphosphorylated tau in dentate gyrus of 
OGT cKO mice. 3D rendering of a z-stack of the dentate gyrus illustrate 
accumulation of tau phosphorylated at T205 in the mossy fibers and cell bodies of 
DG neurons. 
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Figure 2.22: Tau sedementation assay shows no changes in solubility  in OGT cKO mice. 
Insoluble tau was isolated by ultracentrifugation with and without sarkosyl detergent, and there 
were no apparent changes in the solubility of both total tau or pS396 tau levels in OGT cKO 
mice. N=2 for each genotype, and values are normalized to total tau in the input. 
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WB: Total Tau 
Figure 2.23: Protein phosphatase lambda treatment demonstrates that 
changes in apparent molecular weight in tau result from phosphorylation 
state and not alternative 3R vs. 4R splicing. The 50kDa band that represents 
tau shows a higher abundance of the upper band (bold arrow) in OGT cKO mice.  
After treatment with protein phosphatase lambda, the changes in the distribution 
of tau between the upper and lower bands is eliminated, suggesting that apparent 
changes in molecular weight are due to phosphorylation and not changes in the 
expression of 3R vs 4R isoforms. 
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type mouse tau were eliminated, suggesting that these changes were due to tau 
phosphorylation, and not changes in the regulation of tau splicing (Figure 2.23). 
As O-GlcNAc has also been shown to modulate APP processing (52), an 
ELISA was used to quantify changes in amyloid beta peptide levels in 6 month 
old OGT cKO animals. Amyloid precursor protein can be proteolytically cleaved 
to form both 42 and 40-mer peptides, and both peptides are increased in OGT 
cKO mice (6.8 fold and 2.7 fold, respectively; Figure 2.24A). Importantly, the ratio 
of 42/40 peptide also increased 2.5 fold and represents an accumulation of the 
more amyloidogenic 42-mer peptide (53) (Figure 2.24A). Furthermore, at 6 
months, the appearance of plaque-like aggregates was observed by Thioflavine-
S staining (6.9 fold increase) (Figure 2.24B).  
2.2.7 OGT is decreased in human AD brain 
A previous study demonstrated a significant reduction in O-GlcNAcylated 
proteins in the frontal cerebral cortex of AD brains compared to healthy 
individuals (54). A more recent study, suggested that AD brains showed 
significant increases in O-GlcNAcylated proteins in the inferior parietal lobule and 
the cerebellar cortex (55). In light of these conflicting studies, and the dramatic 
neurodegenerative phenotype of the OGT cKO mice, we evaluated whether 
changes in OGT protein levels were evident in human AD tissue. Using 
immunohistochemistry, we quantified OGT protein levels in AD brains with an 
anti-OGT antibody (AL28). Remarkably, a 1.6 fold decrease in OGT protein 
levels was observed in cortical AD neurons (Braak VI) compared to healthy 
control individuals (Figure 2.25). This result suggests that our model of reduced  
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Figure 2.24: OGT cKO mice have increases in amyloid beta peptide and protein 
aggregates. (A) Increases in both amyloid beta 42 and 40-mer peptides are quantified by 
ELISA in 6 month OGT cKO mice, with accompanying increase in the 42/40-mer peptide 
ratio. (B) Thioflavine-S positive aggregates appear in 6 month old OGT cKO mice. **-
P<0.005. Scale bar = 50um. 
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Figure 2.25: AD brain tissues show significant reductions in OGT protein levels. AD brain 
tissues were stained for OGT protein levels with immunohistochemistry. A 1.6 fold reduction in 
OGT protein levels was observed between AD Braak stage VI patients and control healthy 
individuals. Although not statistically significant, Braak IV-V tissues showed a reduction in OGT 
between normal and stage VI levels. Map2 was used as a control to quantify neuronal numbers 
in different slides. **-P<0.005, n=6. 
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OGT represents a disease-relevant pathway. Although not statistically significant, 
Braak IV-V demonstrated a level of OGT that was intermediate, between healthy 
control and advanced stage Braak VI patients. 
2.2.8 The role of Excitotoxicity in Neuronal Death after loss of OGT 
 O-GlcNAc glycosylation has been shown to have a significant 
neuroprotective role in ischemia-reperfusion injuries (4, 56-58). We hypothesized 
that after loss of OGT, stress responses may be impaired and neurons may be 
especially vulnerable to excitotoxicity. To test this hypothesis, we cultured floxed 
OGT cortical neurons, and compared CRE treated (OGT knockout) neurons with 
Cherry control treated neurons (wild-type). After 24 hour glutamate treatments, 
cell viability was assessed with an MTT assay (Figure 2.26). Although the 
experiment was repeated many times, it yielded irreproducible results. Several 
times, OGT KO neurons were significantly more sensitive to glutamate treatment 
compared to wild-type neurons. However, in other experiments, there was no 
difference in excitotoxicity. Many parameters were varied, such as plating 
density, glutamate treatment time, and excitotoxic stimulus (NMDA vs. 
glutamate). Control wild-type neurons (non floxed OGT) were treated with CRE 
or Cherry virus, and showed no change in excitotoxicity. 
2.2.9 Changes in AKT and GSK3β phosphorylation in OGT cKO mice 
 As we had characterized increases in hyperphosphorylated tau, we sought 
to investigate whether key cellular kinases were altered in OGT cKO mice. An 
activating phosphorylation of AKT at S473 was significantly increased in OGT 
cKO mice at 4 months (Figure 2.27A). AKT phosphorylates GSK3β at S9, and  
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Figure 2.26: MTT assays are inconclusive as to whether OGT loss potentiates neuronal 
excitotoxicity to glutamate. Dissociated floxed OGT neurons were treated with cherry control or 
CRE virus on 1DIV, followed by 24 hour glutamate treatment on 6DIV at the indicated 
concentrations. An MTT assay was used to quantify cell death at 7DIV, and representative results 
of several experiments are presented here. A small but significant change in the susceptibility of 
OGT KO neurons (CRE treated) to death after glutamate was detected in several experiments 
(Trial 1 & 2), but not in others (Trial 3). Three and 12 hour treatments with glutamate were also 
tried and showed no significant changes in excitotoxicity (data not shown). Control neurons (wild-
type) were treated with cherry control and CRE virus and showed no change in cell death.  
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Figure 2.27: OGT cKO mice have activated AKT and inhibited GSK3β. (A) OGT ckO mice have 
increased activation of AKT by phosphorylation at S473 at 4 months. (B) Inactivation of GSK3β by 
phosphorylation at S9 is also increased in OGT cKO mice, at both 2 and 4 months. *-P<0.05, **-
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accordingly, GSK3β was found to have increased phosphorylated S9 in OGT 
cKO mice at both 2 and 4 months (Figure 2.27B). This modification represses 
GSK3β activity, and it is unclear how these changes contribute to OGT cKO 
neurodegeneration. 
2.3 Discussion: 
Previously characterized mouse models of OGT knockout were limited by 
an embryonic or early postnatal lethal phenotype, but demonstrated an increase 
in tau phosphorylation. As OGT is clearly necessary for neuronal development 
and regulates key neuronal proteins, we sought to better characterize its role in 
the mature mouse brain. Our αCamKII-Cre mouse produced a gradual knockout 
of OGT in which a subset of hippocampal and cortical neurons were continually 
knocked out from 1 to 6 months. This progressive knockout of forebrain neurons 
led to neuronal loss, beginning at 2 months at about 20%, increasing to over 50% 
by 4 months. Hippocampal neurons were shown to be TUNEL positive, and thus 
undergo apoptosis. In addition, FJ-C was used to quantify degenerating neurons, 
and demonstrated that over 30% of hippocampal neurons were degenerating in 2 
month old OGT cKO mice. 
Although neuronal degeneration and death is observed shortly after loss 
of OGT, we observed degeneration in O-GlcNAc positive neurons as well. When 
examining FJ-C staining, some neurons were positive for both O-GlcNAc and 
FJC. This suggests that neuronal dysfunction observed in OGT knockout 
neurons can spread to nearby wild-type cells. It is likely that the extensive 
neuroinflammation observed and release of cellular contents after apoptosis may 
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contribute to degeneration of OGT positive neurons. The spreading of 
degeneration is thought to play an integral role in the pathology of 
neurodegenerative diseases and is seen in other mouse models (59, 60). 
OGT cKO mice survived well past 6 months even after a ~70% reduction 
in forebrain neurons. During this time several behavioral abnormalities were 
observed. Most mice exhibited an excessive grooming phenotype beginning at 5 
months, which resulted in hair loss and development of skin lesions. This 
phenotype has been observed in mouse models of OCD and schizophrenia (33, 
34). The cause for this phenotype is unclear, although other models suggest that 
cortico-striatal networks and microglia may be involved. Certainly both severe 
cortical degeneration and microglial activation are observed in OGT cKO mice. 
Despite this progressive loss of neurons in the forebrain, 4 month old OGT 
cKO mice retain good motor function, as assessed by a rotarod assay. Increases 
in anxiety are observed at 2 months, and changes in amygdala-dependent fear 
memory are apparent at 2 months before overt loss of neurons. By four months, 
there are significant deficits in both cued and contextual fear-related memory, but 
despite significant reductions in the total number of forebrain neurons (60%), 
OGT cKO mice are still able to make new associations. Furthermore, although 
not statistically significant, place preference tests suggest that short-term 
memory is impaired in OGT cKO mice. These behavioral studies demonstrate 
significant memory impairments that are seen in other AD mouse models.  
Although OGT has been implicated in the regulation of both tau and APP, 
it was not clear whether altering O-GlcNAc signaling in healthy neurons could 
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induce tau and APP pathology. Of great significance is that the observed 
changes in tau phosphorylation and amyloid beta peptide levels in OGT cKO 
mice are produced from endogenous mouse proteins. This is in contrast to most 
AD mouse models that utilize overexpression of mutant human proteins to 
recapitulate disease phenotypes (61, 62). Furthermore, unlike several 
established AD mouse models which require 12 months to generate pathological 
phenotypes, OGT cKO mice display AD phenotypes beginning at 2 months.   
One of the most immediate and striking phenotypes observed in OGT cKO 
mice is gliosis. Both microglia and astrocytes are massively upregulated in the 
entire hippocampal region at 2 months of age, spreading to the cortex by 6 
months. As neurons are clearly undergoing apoptosis, it is likely that glial cells 
are responding directly to degeneration and neuronal loss.  
It has been shown that O-GlcNAc modifies nicastrin, a component of the 
γ-secretase complex that proteolytically cleaves APP (63), and APP itself has 
been shown to be O-GlcNAc modified, although the significance of these 
modifications is not understood (64). We observed increases in the levels of both 
42 and 40-mer amyloid beta peptide, as well as the ratio of 42/40-mer Aβ 
peptide. As the 42-mer peptide is more amyloidogenic, this ratio is a biomarker 
for AD diagnosis (65) and our finding suggests that the changes in APP 
processing that occur in the human disease also occur in OGT cKO mice.  
We observe increases in phosphorylated tau in both axons and soma of 
dentate gyrus neurons, which form neurofibrillary tangle-like inclusions. The 
increases in tau phosphorylation are observed at epitopes (T205, S396, T231) 
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that are associated with paired-helical filamentous tau, which is the major 
component of neurofibrillary tangles. O-GlcNAc modifications have been shown 
previously to regulate tau phosphorylation both by directly competing for 
phosphorylation sites, as well as regulating kinases involved in tau 
phosphorylation (66-68). Importantly, we observe significant AKT activation and 
GSK3β inactivation in OGT cKO mice. This pathway likely plays a role in 
neurodegeneration, although the significance of these changes in our model 
remains to be elucidated. Ongoing studies seek to identify other kinases that are 
responsible for the observed increases in phosphorylated tau after OGT 
knockout. 
Hyperphosphorylation of tau has been shown to affect its solubility, and 
we evaluated this property of tau in OGT cKO mice. Using a tau sedimentation 
assay, no changes in tau solubility were apparent, but we did observe an 
increased amount of a higher molecular weight tau species in OGT cKO mice. 
We hypothesized that this could be due to altered tau isoform expression (3R vs. 
4R) but upon phosphatase treatment, the changes were no longer present and 
thus are likely the result of altered phosphorylation of tau.  
We also observe an increase in Thioflavine-S staining in OGT cKO mice 
at 6 months. These aggregates co-stain with a phospho-tau antibody (T205) 
although they appear to be extracellular. Such Thioflavine-s stained species are 
observed in other AD mouse models and likely represent insoluble protein 
aggregates in OGT cKO mice. 
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As OGT cKO mice display such striking degeneration, we sought to better 
characterize the transcriptional changes that underlie the observed pathology. 
After identifying changes in gene expression by microarray, subsequent WGCNA 
analysis revealed that genes involved in the immune response as well as cell 
cycle arrest were significantly increased in OGT cKO mice at 2 months. While 
immune response activation was expected given the level of gliosis observed, 
the increase in cell cycle arrest gene expression was quite surprising and 
suggests that O-GlcNAc may regulate the pathology of AD through a mechanism 
involving inappropriate cell cycle advancement. Several studies have shown that 
manipulation of O-GlcNAc glycosylation has been shown to perturb cell cycle 
progression (69-71), and inappropriate cell cycle advancement has been shown 
to occur in neurons from the brains of Alzheimer’s disease patients and in 
neurons of various mouse models of AD (72-76). 
 We investigated CDK5, which is essential for repressing neuronal cell 
cycle advancement. A reduction in CDK5 protein was observed in O-GlcNAc 
negative neurons of OGT cKO mice and suggests that neuronal cell cycle re-
entry may be occurring in OGT cKO mice. Future studies are required to 
understand how O-GlcNAc might regulate this process. Furthermore, we 
demonstrate that CDK5 itself is O-GlcNAc glycosylated, although the significance 
of this modification remains to be elucidated.  
 Another interesting possible mechanism for the neurodegeneration in 
OGT cKO mice is increased susceptibility to excitotoxicity. OGT has been shown 
to play an important role in modulating the stress response, and O-GlcNAc 
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modifications have been shown to be neuroprotective in ischemia-reperfusion 
injury models. Our assessment of the effects of OGT knockout on excitotoxicity in 
cultured neurons was inconclusive, with experiments yielding mixed results. 
Future studies could focus on finding other ways to perturb O-GlcNAc levels in 
neurons and evaluate their effects on excitotoxic insults.  
2.4 Conclusion 
Previous studies investigating the role of O-GlcNAcylation in 
neurodegeneration have provided conflicting results, with studies in mice 
suggesting that increasing O-GlcNAc levels can be neuroprotective, while studies 
in C. elegans suggest the opposite (26, 77, 78). To better define the role of OGT 
in adult neurons, we generated a conditional knockout of OGT in the postnatal 
forebrain. Our OGT cKO mouse model demonstrates that a loss of OGT in adult 
neurons directly results in neurodegenerative phenotypes which include neuronal 
loss, inflammation, behavioral deficits, and increases in hyperphosphorylated tau 
and amyloid beta peptide. Furthermore, we find that neurons in human AD tissue 
have significantly reduced levels of OGT, suggesting that our model of OGT 
knockout is representative of the pathology found in the human disease. Future 
insights into the mechanisms that contribute to the observed degeneration in 
OGT cKO mice will facilitate the development of new therapeutic strategies for 
AD. Specifically, understanding the role of O-GlcNAcylation in regulating CDK5 
and cell-cycle progression in neurons is of great interest, as is understanding 
how O-GlcNAc regulates the biology of tau and APP. 
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2.5 Materials and Methods: 
2.5.1 Reagents: 
Histoclear (Electron Microscopy Sciences, 641101-01), Tissue-Tek OCT (Fisher, 
14-373-65), Vectashield (Vector labs, H-1200), Fluoro-Jade C (Millipore, AG325), 
ApopTag Fluorescein Kit (Millipore, S7110), Primary Antibodies: anti-OGT: DM-
17 (Sigma O6264), AL-25/28 (Dr. Gerald Hart, Johns Hopkins), anti-O-GlcNAc: 
RL-2 (Pierce, MA1-072), anti-tau: p205 (Invitrogen 44738G), p231 (EMD 
Millipore, AB9668), AT180 (Pierce, MN1040), p396 (Abcam, 32057), tau-5 
(Millipore, MAB361), AT8 (Pierce, MN1020), anti-Microglia: Iba-1 (WakoUSA, 
019-19741), anti-astrocytes: GFAP (Cell Signaling, 3670P), anti-neuronal nuclei: 
NeuN (Millipore, MAB377), anti-CDK5: CDK5 (Santa Cruz, SC-173), anti-PCNA: 
PCNA (Abcam, 18197), anti-GFP: GFP (Life Technologies, G10362), anti-tubulin: 
a-Tubulin (Sigma, T9026). Secondary Antibodies: Alexafluor 405, 488, 546 goat 
anti-mouse (Invitrogen), Amyloid beta ELISA 1-40, 1-42 (Covance, SIG-38954, 
38956) 
2.5.2 Mice 
C57/Bl6 backcrossed CamKIIa-Cre mice were a kind gift from Dr. Mary Kennedy, 
and were maintained and genotyped using established procedures (32). OGT 
floxed mice (B6.129-Ogttm1Gwh/J) were purchased from Jackson Labs (004860) 
and backcrossed into the C57/Bl6 background. Genotyping was done following 
JAX protocols. Mice were group housed whenever possible, and all experiments 
were approved by the IACUC protocols at Caltech. 
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2.5.3 Immunohistochemistry 
Perfusion: Mice were trans-cardially perfused with 4% paraformaldehyde (PFA) 
fixative. Brains were dissected and fixed in 4% PFA overnight at 4 C, followed by 
cryoprotection with 15-30 % sucrose overnight. Hemispheres were embedded in 
OCT medium and snap frozen in dry ice/methanol. Sagittal sections at 20 um 
were collected with a cryostat and stored free floating in an ethylene glycol 
solution stored at -20 C. Slices were stained with primary antibody in 2% normal 
goat serum with 0.1% Triton-X 100 in PBS over night at 4C. After washing 3 x 5 
min in PBS, slices were incubated with secondary antibodies at 1:400 dilution for 
1 hr at room temperature. Slices were washed as before and mounted onto 
slides, allowed to dry, and coverslipped with vectashield. Tissue sections were 
coded and imaged with a Zeiss 700 confocal microscope. Images were collected 
for each region of interest from slices spaced 100 um apart through the region. A 
minimum of 12 slices were quantified for each animal. 
Nissl staining: Slices were incubated in 100% EtOH for 2 min, Histoclear for 2 
min, followed by re-hydrating in 100, 70, 50% EtOH for 2 min each. Slices were 
then stained with 0.1% Cresyl Violet solution for 10 min, rinsed in distilled water, 
and differentiated in 95% EtOH with 10% acetic acid for 10 seconds, rinsed in 
100% EtOH, and cleared for 2m in in Histoclear. Slices were then mounted and 
imaged. 
Fluorojade-C and Thioflavine-S staining: Slices were incubated in 0.06% 
potassium permanganate solution for 10 min, followed by a water rinse, and then 
transferred to a 0.0001% solution of Fluorojade-C in 0.1% acetic acid, or a 0.05% 
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Thioflavine-S solution in 50% EtOH for 10 min, rinsed in water (or 50% EtOh for 
Thioflavine-S), then mounted and imaged. 
AD human tissue: samples from control (n=6) and Braak VI (n=8) were acquired 
from Dr. Harry Vinters, UCLA Medical School. Slices were pre-treated with heat 
antigen retrieval in citrate buffer pH 6, followed by treatment with sudan black 
and staining as described above. Four representative regions were imaged in 
each slice, and at least 4 slices were imaged per individual. Images were coded 
and researchers were blind to sample ID while qualitatively scoring OGT protein 
signal with a scale from 1-5. Non-specific signal from autofluorescent particles 
necessitated a qualitative approach. 
Golgi Stain: Golgi stain was performed following manufacturers protocol (FD 
Neurotech). Fresh brains were submerged into a mixture of equal volumes of 
solutions A and B, stored at RT for 2 weeks in the dark. Solution was replaced 
after 6 hours. Tissue was transferred to solution C, for 72 hours in the dark, again 
with one replacement of solution after 24 hours. 200um sections were cut on a 
vibratome, and mounted on gelatin-coated slides. After drying, slides were rinsed 
in ddH2O and stained by submerging in a mixture of 1 part solution D, 1 part 
solution E, and 2 parts dd H2O for 10 min. Sections were rinsed in ddH2O twice 
for 4 min each, dehydrated with successive ethanol solutions, and finally in 
absolute ethanol 4 times, 4 min each. Slices were cleared in Histoclear and 
coverslipped with permount. 
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2.5.4 Behavioral Studies 
Rotarod: Rotarod test was performed as described previously (79). Briefly, 
latency to fall from an accelerating rotarod (Ugo Basile) beginning at 5 rpm to 40 
rpm over 240 s was scored. Mice were allowed to stay on the rotarod for a 
maximum of 300 s. Mice were trained for two consecutive days, with two trails 
per day with a 10 min intertribal interval. On testing days, two trials were 
performed and averaged. 
Open Field: Open field tests were performed as described previously (79). 
Briefly, mice were placed in the lower left corner of a 50 x 50 cm white box and 
activity was recorded for 10 min by a ceiling-mounted video camera. Total 
distance traveled and center entries were scored. 
Fear Conditioning: Fear conditioning was performed as described previously 
(80). Briefly, mice were placed in the chamber (Med Associates) for the first time 
and allowed to explore for 120 s after which an audible tone was played for 30 s. 
During the last 2 seconds of tone, a 0.7 mA foot shock was applied. Another tone 
was played at 180 s again for 30 s with another foot shock applied for the last 2 s 
of the tone. Mice were placed back into their cages. After 24 h, mice were placed 
in the same chamber and monitored for 5 min to quantify context dependent 
memory. Mice were placed into home cages for 1 hour, and then placed into an 
altered context chamber (altered scent, shape, lighting) for 5 min, with a tone 
playing for the last 180 seconds. All freezing quantification was done by Med 
Associates software, and freezing was normalized to pre-tone freezing % for 
cued tests. 
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Y-Maze: Animals were introduced to the Y-Maze and recorded for 5 min. Arms 
entries were noted and sequential overlapping triplets were analyzed to 
determine whether mice entered new arms each time, or revisited the same arm  
twice within each triplet of arm entries. Percent alternation was quantified by the 
number of alternating triplets, divided by the total number of triplets. 
Place Preference: Mice were introduced to an open field with two objects 
(children’s plastic toys), one in each of the upper quadrants of the box. Objects 
were placed at least 6 inches from the wall of the box, to allow room for mice to 
walk around the object without investigating. Investigations were classified as 
distinct head pointing or sniffing within 1 inch of the object. Animals were 
recorded for 5 min and removed. During a 5 min interphase period, one of the 
objects was moved from the upper right quadrant to the lower right quadrant. 
Mice were replaced and recorded for another 5 min, and investigations were 
quantified. Increases in the number of investigation events represented an 
increase in interest in the object. The experiment was conducted with normal 
fluorescent lighting, and in the future using the red light or dimmed lighting may 
provide a more suitable environment. 
2.5.5 Microarray 
Hippocampal tissue was isolated from 3-week or 2-month old mice and flash 
frozen in nuclease-free tubes.  The hippocampal samples were stored in the -
80oC until RNA extraction.  Total RNA was extracted using RNeasy kit with 
DNase treatment.  Following RNA extraction, the samples were either sent to 
Phalanx Biotech Group for microarray analysis or reverse transcribed using the 
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iScript cDNA Synthesis Kit for qRT-PCR.  Following reverse transcription, the 
cDNA was used for qPCR using Perfecta SYBR Green Fastmix with ROX on the 
AB7300 Real Time System. The qRT-PCR primers used for this study are listed 
in the supplemental Table 4.  Statistical significance of qRT-PCR results was 
determined using an unpaired t-test. Reported p values for the microarray results 
from this study are Bonferroni-corrected (81). 
2.5.6 Chemoenzymatic Labeling 
Chemoenzymatic labeling of mouse brain lysate was performed as described 
previously (82). Briefly, 200 ug mouse cortical lysate labeled with UDP-GalNAz 
with GalT enzyme as described, and reacted with alkynyl-biotin. Biotinylated 
proteins were pulled down with streptavidin-conjugated agarose beads, washed, 
eluted, and subjected to SDS-PAGE electrophoresis followed by western blotting 
with CDK5 antibody. Specificity of the reaction was confirmed by omitting GalT 
enzyme. 
2.5.7 TUNEL Labeling 
TUNEL labeling was performed using manufacturer’s protocols with one 
modification. Briefly, slices were treated with proteinase-k for 15 min, washed, 
and microwaved for 30 s in 10mM citrate buffer pH 3. Slices were then incubated 
with TdT enzyme for 1 h at 37 C. After subsequent wash steps, anti-digoxigenin 
conjugate was applied for 1 h at room temperature. Slides were then washed and 
mounted. Co-staining with another primary antibody was done after anti-
digoxigenin incubation. 
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2.5.8 Tau Sedementation Assay 
Whole brains were homogenized in  600 uL tissue homogenization buffer (THB) 
with PIC and PMSF using glass teflon douncer (about 10 dounces). 50mM Tris 
HCl pH 8, 274 mM NaCl, 5 mM KCl, 2 mM EDTA, 2 mM EGTA, 30 mM NaF,  
1x protein phosphatase inhibitor cocktail containing sodium vanadate, beta 
glycerophosphate, and sodium fluoride, add fresh 1mM PMSF, protease inhibitor 
cocktail (Roche) with EDTA. Lysates were then spun down at 13000 x g at 4C for 
20 minutes. Supernatant was collected, and the pellet was re-extracted with 
another 600 uL of THB as before (10 dounces with teflon douncer). After 
spinning down at 13000 xg at 4C for 20 minutes, supernatants from extraction 1 
and 2 were combined. 25 uL was saved for the “input”. The remaining sample 
was divided into 2 equal portions for a high speed sup and high speed post 
sarcosyl sup. To the sarkosyl portion, add N-lauryl sarcosyl (20% stock solution) 
to a final 1%, and then shake in 37C incubator for 1h. The two fractions were 
then ultracentrifuged as follows: The volumes were brought up in their respective 
buffers (THB +/- 1% sarcosyl) to almost fill the ultracentrifuge tubes. They were 
then spun down at 100,000 x g for 45 min (34,163 rpm on swing rotor). A portion 
of the sup was collected and the rest discarded (be careful not to displace the 
pellet which is small and hard to see). The pellets were resuspended in 2x 
loading dye, and run on a gel. Blot with tau 5 overnight and p-tau. 
 2.5.9 Tensor Based Morphometry Analysis 
MRI scan of fixed brains in skull was carried out with the assistance of Joe 
Gallagher and Dr. Russell Jacobs, at the Biological Imaging Facility of the 
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Beckman Institute. Briefly, scanned images were processed by stripping the skull 
from the brain. MIPAV software was used to visualize the MRI data. MRIcro was 
used to analyze the changes in volume.  
 2.5.10 MTT Excitotoxicity Assays 
Dissociated floxed OGT neurons were plated at 15-30,000 cells per well of a 96-
well plate. Neurons were treated with cherry control or CRE virus on 1DIV, 
followed by 24 hour glutamate treatment on 6DIV (0-500uM). After 24 hours, 
MTT at 0.125mg/mL final concentration was added to the wells for 1 hour. Wells 
were aspirated, and 100uL of DMSO was added to solubilize formazan. Wells 
were read at 550 nm.  
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Chapter 3: Investigating the regulation of OGT 
3.1 Introduction 
Understanding the regulation of OGT is an extremely important next step 
to uncovering how O-GlcNAc glycosylation contributes to cellular signaling in 
healthy and diseased states. Furthermore, as O-GlcNAcylation of several 
disease-related proteins clearly contributes to pathology, controlling such 
modifications represent a significant area for therapeutic development. 
Investigations of OGT enzyme activity and specificity have mainly focused on 
characterizing the TPR domains of OGT, and defining how substrates interact 
with OGT. As described in the introductory chapter, a few OGT interacting 
proteins have been characterized, but most substrate-OGT interactions have not 
been explored.  
OGT regulation by post-translational modification is also poorly 
understood, although it has been shown that OGT is both O-GlcNAc modified (1) 
and phosphorylated (2, 3). Studies have demonstrated that OGT is 
phosphorylated by CaMKIV and AMPK, and represent the only examples to date 
that describe the role of post-translational modifications on OGT activity. 
Specifically, CaMKIV was shown to modify OGT dynamically in response to KCl 
depolarization in a calcium influx dependent manner in a neuroblastoma cell line 
(3). This phosphorylation was accompanied by an increase in OGT enzymatic 
activity, which was demonstrated both in vitro with an activity assay and by an 
increase in O-GlcNAc modified protein staining with an O-GlcNAc antibody 
(RL2). Furthermore, a CaMKIV inhibitor, as well as CaMKIV shRNA was used to 
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show that CaMKIV inhibition or depletion eliminates OGT phosphorylation after 
KCl. Although the site of CaMKIV phosphorylation of OGT was not identified, this 
was the first study to characterize a potential mechanism for OGT activation.  
A more recent study demonstrated that AMPK phosphorylates OGT at 
T444 and activation of AMPK alters OGT substrate specificity and induces 
nuclear localization (2). Furthermore, OGT nuclear localization was shown to 
increase O-GlcNAcylation of nuclear proteins, as well as acetylation of L9 of 
Histone 3 in myotubes. This suggests that AMPK modification of OGT may play a 
role in regulating OGT activity on nuclear proteins and may alter epigenetic 
factors through histone dynamics. AMPK was shown to be activated by O-
GlcNAc as well, suggesting extensive crosstalk between the two enzymes. 
Although these two examples provide valuable insight, they are limited in their 
scope and do not identify the role of these post-translational modifications of 
OGT in altering O-GlcNAcylation of specific substrates, or the functional 
consequences of these changes.  
Given our incomplete understanding of how OGT is regulated, a previous 
graduate student in our lab, Dr. Jessica Rexach, sought to identify sites of 
phosphorylation by subjecting OGT overexpressed and purified from SF9 cells, 
as well as OGT that was phosphorylated in vitro by CaMKIV, to mass 
spectrometry (4). These studies identified several phosphorylation sites, 
including S993, S994, S481, which are all on or near the C-terminal catalytic 
domain of OGT. Additional sites near the N-terminus (S151, S298) were also 
identified. Importantly, phosphorylation of OGT was detected in response to KCl 
97 
 
depolarization in neurons, using radioactive orthophosphate (4). Dr. Rexach 
further demonstrated that O-GlcNAc glycosylation increases upon KCl 
depolarization in cortical mouse neurons, and that this increase was dependent 
on calcium influx, and downstream of CaMKII activation. She also showed that 
overexpression of phosphorylation-deficient S994A and S993A mutant OGT 
reversed a neurite inhibition phenotype observed when overexpressing wild-type 
OGT in cortical mouse neurons. This finding suggested that phosphorylation at 
these sites may alter OGT activity, as it affects neurite outgrowth differently than 
wild-type OGT overexpression.  
In order to better understand this phenomenon, we sought to generate 
phosphorylation-specific antibodies to facilitate the detection of OGT 
phosphorylation at these sites and investigate the mechanisms regulating these 
phosphorylation events. Phosphorylation-specific antibodies have been used 
extensively to investigate the role of phosphorylation on proteins in response to 
cellular signaling (5). For instance, phosphorylation-state specific antibodies for 
amyloid precursor protein (T654, S655) have shown that phosphorylation at 
specific sites are regulated in a cell-cycle dependent manner (6). Furthermore, 
phospho-specific antibodies were used to demonstrate that synapsin I is 
dynamically phosphorylated in response to brain-derived neurotrophic factor and 
nerve growth factor stimulation through a MAP kinase signaling pathway (7). This 
phosphorylation of synapsin I results in reduced G-actin polymerization and may 
modulate synaptic plasticity in response to neurotrophin signaling.  These studies 
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illustrate the utility of developing phosphorylation-specific antibodies to facilitate 
mechanistic studies of OGT regulation.  
Furthermore, to evaluate whether phosphorylation-deficient mutants 
S994A and S993A exhibit changes in their catalytic activity, we apply several 
OGT activity assays that were previously developed. A tried and true radioactive 
assay has been used in the past to evaluate OGT in a variety of contexts, from 
complex lysates to purified enzyme (3, 8). The assay relies on tritiated UDP-
GlcNAc as a substrate donor for OGT and incorporation of tritiated GlcNAc onto 
a model casein kinase II peptide substrate is quantified by scintillation counting. 
Furthermore, a small molecule Thorson sensor was previously shown to be 
sensitive to UDP concentrations, so we reasoned that this sensor could be used 
to monitor the liberation of UDP as a proxy for OGT enzymatic activity (9, 10). 
This small molecule sensor relies on zinc-mediated coordination of UDP to 
induce a change in fluorescence intensity. Finally, a previously developed FRET 
probe was used to assess changes in OGT activity in live cells in response to 
cellular stimuli (11, 12). The FRET probe consists of a construct with the 
following components: fluorescent protein, casein kinase II peptide substrate, O-
GlcNAc binding lectin, fluorescent protein. As the casein kinase II substrate 
becomes O-GlcNAcylated, the lectin binds the peptide, bringing the two 
fluorescent proteins closer together, which increases FRET efficiency. It was 
shown previously that this process is reversible when OGA removes O-GlcNAc 
from the substrate. The results of these various assays are described in the 
following sections. 
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3.2 Results 
3.2.1 Neurite Outgrowth  
Previously, neurite outgrowth studies demonstrated that S993A and 
S994A mutant OGT proteins produced longer neurites compared to wild-type 
OGT overexpression (4). Importantly, this study used different plasmid 
backbones to express the mutant and wild type OGT proteins. We wanted to use 
the same backbone for both proteins so that protein expression levels would be 
the same, thus allowing for a more valid comparison of the effects of S993A, 
S994A, and WT-OGT overexpression. E15 cortical mouse cultures were 
dissected and electroporated separately with either D925A OGT (catalytic dead 
control), WT-OGT, S994A OGT, or S993A OGT expression constructs. The 
control for our experiments was a catalytic dead form of OGT (D925A), as the 
GFP construct originally used as a control was potentially toxic to the neurons.  
The neurite outgrowth assay shows that WT-OGT overexpression in 
neurons causes a decrease in total neurite length, compared to a control 
expressing catalytic dead OGT (Figure 3.1). Importantly, overexpression of either 
S993A or S994A OGT rescues this phenotype.  
3.2.2 Generation of phosphorylation-specific antibodies  
After discovering the effect of the S994A mutant on neurite outgrowth, we 
decided to investigate the site further by generating phosphorylation-specific 
antibodies which would facilitate in vitro studies of OGT phosphorylation in 
neuronal lysates. One month following the immunization of rabbits with OGT 
peptides containing phosphorylated S993 or S994 sites, sera were collected and  
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Figure 3.1: OGT overexpression 
inhibits neurite outgrowth, and mutant 
OGT expression rescues this 
phenotype. OGT constructs were 
electroporated into neurons, and neurite 
outgrowth was quantified after 3DIV. A 
catalytic dead form of OGT was used as a 
control. Expression of wild-type OGT 
inhibits neurite outgrowth, whereas 
expression of serine to alanine mutants of 
phosphorylation sites (S993, S994) has no 
effect on neurite outgrowth. This finding 
suggests that phosphorylation of OGT at 
these sites may regulate its activity. 
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dot blots were used to evaluate the specificity of the antibodies (Figure 3.2). The 
dot blots were spotted with 50, 25, or 5ug of the peptide antigens, which 
contained either phosphorylated serine residues at S993 (PS993), S994 
(PS994), or neither (S993/4). Sera demonstrated improved specificity for desired 
antigens over time. The best samples were taken further, and antibodies were 
purified with sepharose columns containing the peptide antigen of interest. 
After affinity purification, antibody was concentrated and re-evaluated with 
dot blots, and show specific binding to only the desired peptides (Figure 3.3A). 
Antibodies were then used to blot cortical lysates. It is evident that these purified 
antibodies have several non-specific interactions (Figure 3.3B). In order to 
confirm that the antibodies recognize OGT, an immunoprecipitation (IP) of 
exogenously expressed FLAG-OGT with FLAG beads was performed and the 
purified phosphorylation-specific antibodies were evaluated by western blot 
(Figure 3.3C). None of the phosphorylation-specific antibodies were able to 
detect FLAG-OGT. 
3.2.3 OGT Activity Assays 
Demonstrating a significant change in OGT enzyme activity after mutation 
of a phosphorylation site would strongly suggest that phosphorylation of OGT at 
these sites regulates its activity. We attempted two different strategies to assess 
OGT enzymatic activity in vitro. First, a previously developed radioactive activity 
assay was used to assess OGT activity in vitro after overexpression in 293T cells 
and purification with FLAG beads (3, 8). Reproducibly, S994A/E mutations in 
OGT resulted in a significant decrease in OGT activity, comparable to a catalytic  
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Figure 3.2: Phosphorylation-specific 
antibodies show changing specificity and 
affinity depending on sera collection date. 
Dot blots were used to assess specificity of 
phosphorylation-specific antibodies. Peptides 
of either phosphorylated S993, S994, or non-
phosphorylated S993&4 were adsorbed to 
nitrocellulose membranes at 50, 25, and 5 ng 
per spot. Sera collected from three separate 
bleeds were used to assess specificity and 
affinity. The most promising bleeds were 
purified to isolate phospho-specific antibodies 
for validation on purified OGT. 
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WB: α-pS993 
50 ng 
Figure 3.3: Purified phospho-specific OGT antibodies have high specificity for 
OGT peptides but not full length protein. Dot blots were used to assess 
specificity of phosphorylation-specific antibodies after affinity purification. (A) 
Peptides of either phosphorylated S993, S994, or non-phosphorylated S993&4 
were adsorbed to nitrocellulose membranes at 50 ng per spot. (B) Purified 
antibodies were used to probe cortical lysate, and s993/4 antibody bound a protein 
at the molecular weight of OGT. (C) Immunoprecipitation of WT OGT or S994A OGT 
with FLAG antibody probed by α-pS994 and α-S993/4 shows no colocalization with 
FLAG , suggesting that the antibodies may not recognize full length OGT. It is 
unclear why α-S993/4 antibody recognized OGT out of lysate in B but not IP OGT in 
C. 
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dead mutant (D925A) of OGT (Figure 3.4). Because we are most interested in 
the role of this regulatory modification in response to neuronal depolarization, we 
moved into neurons to see if KCl depolarization affected OGT activity. In 
neurons, initial studies have shown that S994A mutant OGT is indistinguishable 
from wild-type OGT. More replicates are needed to draw conclusions, and 
optimization of assay conditions would improve signal to noise, which is likely 
affecting these initial results.  
In an effort to improve the throughput of the OGT activity assay, a Thorson 
probe was used to assess UDP concentration, which is a product of OGT 
enzymatic activity (9, 10). Optimization of the assay revealed that detergent, 
DTT, and FLAG beads attenuated Thorson probe signal, and these normal 
components of the OGT activity assay were omitted. Unfortunately, after multiple 
rounds of optimization, no response to OGT activity was observed using the 
Thorson sensor (Figure 3.5). 
3.2.4 FRET probe 
In order to evaluate changes in OGT activity either in response to cellular 
signaling or modulation of post-translational modifications, we sought to utilize a 
FRET assay that would respond to dynamic changes in OGT activity in live cells. 
A previously developed FRET probe was expressed initially in 293T cells, to 
confirm efficient expression (11, 12). Distinct fret probes were successfully 
shown to target to the nucleus and plasma membrane, as well as generally 
throughout the cell. FRET probe was then extended to N2A cells, and neurons 
(Figure 3.6).  
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Figure 3.4: In vitro radioactive OGT activity assay shows 
decrease in S994A mutant activity comparable to a catalytic 
dead OGT mutant. OGT constructs were transfected into 293T 
cells and immunoprecipitated with FLAG beads. Activity was 
measured by incorporation of tritiated GlcNAc onto a casein 
kinase II peptide. S994A and S994E mutant OGT show 
decreased activity, comparable to a catalytic dead OGT mutant, 
D925A. N=3. ***-P<0.00005. Ongoing studies are investigating 
changes in the activity of OGT and OGT mutants in N2A cells 
upon neuronal depolarization. 
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Figure 3.6: FRET probes localize to the plasma membrane and nucleus. 
General, plasma membrane targeted, and nuclear targetd O-GlcNAc FRET probes 
show expected distribution after expression in neurons.  
General Plasma Membrane  Nuclear 
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 After confirming efficient targeting and expression, N2A cells were 
transfected with the general FRET probe and FRET efficiencies were analyzed in 
response to KCl depolarization. Previous work established that OGT is activated 
and O-GlcNAcylation increases dynamically in response to KCl depolarization, as 
quickly as 2-5 minutes after treatment. Upon depolarization, a general increase in 
fluorescence for both CFP and YFP are observed, and the ratio of YFP to CFP is 
not significantly changed (Figure 3.7) in the raw signal intensities. Using the 
RiFRET program to visualize changes in FRET efficiencies, it is apparent that 
certain areas of the cell display increases in FRET efficiency upon KCl 
depolarization, but these changes are small and are likely averaged out when 
quantifying total raw signal intensities. As a control, unglycosylatable FRET 
probe was shown to be unresponsive to KCl depolarization (Figure 3.8). 
Furthermore, treatment with PBS instead of KCl also showed no changes in 
FRET probe fluorescence. 
3.3 Discussion  
Overexpression of wild-type OGT was shown previously to result in 
decreased neurite outgrowth, and S994A OGT was shown to rescue this 
phenotype. In this study, these results were replicated, and S993A was also 
shown to rescue the wild-type OGT overexpression phenotype. Dr. Rexach had 
previously shown that glycosylation of CREB represses CREB-regulated gene 
transcription. Many of these transcriptional changes contribute to neuronal 
growth, and thus increased O-GlcNAcylation could potentially inhibit neuronal 
growth through a CREB dependent mechanism. Dr. Rexach also showed  
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Figure 3.8: Control FRET probe shows no changes in OGT activity after KCl 
depolarization. Timecourse shows no change in FRET efficiency after KCl 
depolarization (t=0) with control (unglycosylatable) FRET probe. 
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that the addition of CREB siRNA eliminated the reduction in neurite outgrowth 
after wild-type OGT expression. Given these findings, our working hypothesis is 
that phosphorylation at S993 or S994 activates OGT, and that S993A and S994A 
constructs are less active, or unable to be activated.  
To study these phosphorylation sites further, phosphorylation-specific 
antibodies were generated, to aid in the detection of these modified forms of 
OGT in response to specific cellular stimuli. These antibodies would allow for the 
use of specific kinase inhibitors (such as CaMK inhibitors) to probe for the 
dependence of kinases for phosphorylation of OGT. Antibody specificity was 
determined to be excellent with dot blot assays, especially after affinity 
purification on phospho-peptide sepharose columns. S993/4 antibody appeared 
to detect OGT in complex cortical lysates; however, none of the antibodies 
appeared to detect OGT in purified, immunoprecipitated samples. It is possible 
that some form of cellular induction is required to generate sufficient quantities of 
phosphorylated OGT to provide enough sample for detection. 
As the phosphorylation-specific antibodies continue to be evaluated, a 
variety of methods to examine OGT activity in vitro were used in an attempt to 
quantify possible changes in mutant OGT activities. In the most robust OGT 
activity assay, the radioactivity assay, S994A/E mutants were shown to have 
significantly reduced activity, comparable to that of catalytic dead (D925A) OGT 
in 293T cells. Although this cell type is not very relevant to our neurite outgrowth 
study, it provides promising evidence that these phosphorylation sites have a 
regulatory role. Attempts to extend this study in neurons were unsuccessful, due 
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to limitations in the amount of OGT that can be transfected into neurons via 
electroporation. Isolation of small amounts of OGT via FLAG beads provides 
many opportunities for experimental error, and represents a significant challenge 
when assay signal to noise is not ideal. Moving forward, it may be important to 
optimize the assay conditions, or find strategies to increase the amount of OGT 
that can be isolated from neuronal samples to yield more reproducible data in 
neurons.  
The Thorson sensor assay clearly showed that with the current assay 
conditions, no change in UDP concentration is detectable. It is likely that this 
assay is not sensitive enough to detect OGT activity in this manner, and although 
it would greatly improve the throughput of OGT activity assessment, this assay 
does not appear to be a viable option. 
Finally, the FRET probe was shown to respond to KCl depolarization, and 
both treatment with PBS, and KCl depolarization of a non-glycosylatable control 
probe yielded no response. Despite the observed change in FRET efficiency 
after KCl depolarization, the dynamic range of the probe is limited in its current 
state, and likely would require increasing FRET probe expression, or more 
rigorous data analysis to serve as a useful assessment of OGT activity in live 
cells. Using the RIFRET program, it appears that certain regions of the cell has 
significant increases in FRET efficiencies upon KCl depolarization; however, it is 
unlikely that these changes are large enough to effectively serve as a proxy for 
OGT activity in live cells. Furthermore, even if these changes increased after 
optimization, assessment of mutant OGT proteins would only be possible if 
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endogenous wild-type OGT was eliminated in the cells. A more tractable target 
would be to treat the cells with specific perturbations, such as calcium chelators 
or pathway inhibitors, to see whether they have an effect on OGT activity rather 
than point mutations. 
3.4 Conclusion 
We have begun to characterize the significance of the S993 and S994 
phosphorylation sites of OGT and our results support previously acquired data 
which show that overexpression of S993A or S994A OGT rescues the inhibition 
of neurite outgrowth observed after wild-type OGT overexpression. 
Phosphorylation-specific antibodies were generated but are currently limited in 
their utility as they specifically recognize their peptide antigens, but not full-length 
OGT. Evaluating additional production bleeds or optimizing the affinity 
purification procedure may improve antibody characteristics. Furthermore, it will 
be important to evaluate the antibodies in response to a cellular stimulus that is 
expected to enhance OGT phosphorylation, such as KCl depolarization. New 
antibodies could be generated at Caltech’s hybridoma facility, where monoclonal 
antibodies could be tested for specificity and affinity to full-length phosphorylated 
protein. A significant challenge would be to obtain pure phospho-OGT for 
screening purposes, but if possible this may provide a viable strategy moving 
forward. 
The radioactive activity assay shows that S993A and S994A mutant forms 
of OGT have a significant reduction in OGT activity, compared to wild-type in 
293T cells. This study will be pursued in neurons, and enhancing reproducibility 
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of the assay by increasing the signal to noise ratio is a key first step. Both the 
Thorson and FRET probe assays do not appear to be sufficiently sensitive to 
reliably assess OGT activity, and would need to be optimized further to have 
utility in this capacity. One possibility is to acquire another O-GlcNAc fret probe 
that is based on CaMKII dynamics that has recently been described (13).  
If it were possible to demonstrate that mutant (S994A) OGT activity was 
not changed by KCl depolarization in neurons or neuron-like cells, and that wild-
type OGT activity was induced by this stimulus, this would support our 
hypothesis that phosphorylation of OGT at S994 activates it downstream of KCl 
depolarization, calcium influx, and CaMKII activation.  
 
3.5 Methods 
3.5.1 Neurite outgrowth assay 
Cortical neurons were isolated from E15 C56Bl6 mice and electroporated 
with 10ug of pLEMPRA WTOGT, D925A OGT, S994A OGT, or S993A OGT with 
the AMAXA nucleofector system (program K009). After electroporation, the 
neurons were plated on poly-DL-lysine coated coverslips at a density of 25,000 
neurons / cm2 in Neural Basal Medium, 10% FBS, 2 mM Glutamax-l (Invitrogen). 
Four days later, the cells were fixed with 4% paraformaldehyde 4% sucrose in 
PBS for 20 min at RT, washed twice with PBS, once with H2O, mounted onto 
glass slides using Vectashield mounting medium with DAPI, and sealed with 
clear nail polish. Cells were imaged using a Nikon Eclipse TE2000-S inverted 
microscope, and images were obtained with Metamorph software using a 40x 
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objective. Neurite lengths were quantified using NeuronStudio (Version 0.9.92, 
CNIC, Mount Sinai School of Medicine). 
3.5.2 Generation of phosphorylation-specific antibodies 
Purchased peptides corresponding to amino acids 989-998 were 
synthesized with phosphorylated serines at 993 or 994, or non-phosphorylated at 
both sites (pS993, pS994, S993/4). Peptides were conjugated to thyroglobulin 
(Pierce) and sent off to Cocalico labs for antibody production. Peptides were 
injected into rabbits on days 1, 14, 21, and 35 and monthly thereafter. Test 
bleeds were collected after one month and production bleeds were collected 
once a month thereafter.  
3.5.3 Dot blots and Westerns 
Sera were tested by dotting 50, 25, or 5 ng of peptide onto nitrocellulose 
membrane and sera were blotted with the western protocol in Chapter 2. Sera 
were purified by anti IgG conjugated to sepharose first, following manufacturer’s 
protocol (Pierce). Then, peptides were conjugated to sepharose beads with a 
terminal cysteine, following manufacturer’s protocol (Pierce). Purified antibodies 
were concentrated to 1 mg/ml. 
3.5.4 KCl depolarization of neurons 
Neurons were silenced with 1uM tetrodotoxin (TTX) and 10 uM D-AP5 for 
12 hours before addition of 55mM KCl. Cells were then quickly washed in ice 
cold PBS and lysed on plate in 2% SDS with protease inhibitors and 
phosphatase inhibitors. Lysates were sonicated twice at 20% power for 10 
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seconds, and centrifuged at 20kg for 5 min to pellet cellular debris. Protein 
concentrations were determined by BCA assay (Pierce). 
3.5.5 OGT Activity Assays 
Radioactive asasys were run essentially as described previously. Briefly, 
cells were lysed in 20mM Tris 7.5, 10mM MgCl2, 1mM EDTA, PMSF/PIC, 1mM 
Na2VO4, 10mM NaF, in the presence or absense of 1% NP-40. Lysates were 
spun down at max G’s for 10 min, and supernatants were incubated with FLAG 
beads for 1 hr at 4C, end over end. FLAG beads were washed 1x in lysis buffer, 
and then once more in transferase assay buffer (TAB), 20mM Tris 7.5, 10mM 
MgCl2, 1mM EDTA, 1mM DTT. An aliquot of FLAG beads was reserved for WB 
to quantify OGT protein levels in each sample. Activity assays were run in 40ul of 
TAB, with 1mM casein kinase II peptide (genscript, PGGSTPVSSANMM) and 
0.2-0.4 uCi tritiated UDP-GlcNAc (Perkin Elmer, NET434050UC). Reactions 
were run at RT for 2 hours end over end, quenched with 50mM formic acid, 
500mM NaCl, and peptides were isolated with C18 spin columns (Pierce 89873). 
Peptides were eluted into 7mL of aqueous compatible scintillation fluid, and 
counted. Samples were run in triplicate whenever possible. 
3.5.6 FRET Assay 
293T, N2A, or neurons grown on glass bottom plates (In Vitro Scientific) 
were transfected with various FRET probe constructs, allowed to grow for 2-3 
days and imaged. At each time point, three images were taken: CFPex, CFPem; 
CFPex, YFPem; YFPex, YFPem. Generally images were acquired with the 63X 
objective on a Zeiss LSM 700. Time courses were taken every 10s to 1m and live 
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cells were imaged for 2-5 min before the addition of KCl (55mM final 
concentration). Typically, 1mL of the plating medium was taken up into a bulb 
pipette along with KCl, and expelled into the dish at the appropriate time. Images 
were analyzed in ImageJ (NIH) and intensities for CFP and YFP (CFPex) were 
quantified. The RiFRET plugin was used to visualize the changes in FRET 
efficiencies. 
3.5.7 Thorson Assay 
FLAG-tagged OGT was expressed and purified as described in OGT 
activity assays. Following immunoprecipitation, OGT was eluted off FLAG beads 
with 3X FLAG peptide (Sigma, F4799) at 100 ug/mL with 3 elutions of 10uL each 
for 30uL of beads. 2uL was saved for a western blot to quantify protein levels. 
Reaction conditions were as follows: 50mM Hepes 7.5, 6 mM MgCl2, 0.6 mM 
ZnCl2, 2.5 uM Thorson sensor, 1 mM casein kinase II peptide, 10 uL eluent from 
OGT IP. When ready to read, UDP-GlcNAc was added to a final concentration of 
200 uM and plates were read at 488 nm. 
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Appendix I: Developing Tools to Study OGT 
A.1 Introduction 
 A major goal in the O-GlcNAc field is to investigate the role of O-GlcNAc 
transferase (OGT) in cellular signaling events, and to understand the regulation 
of OGT by TPR mediated interactions or post-translational modifications. This 
has proven to be quite challenging, because widely used strategies of generating 
stable knockdown or knockout cell lines for OGT are not possible due to its 
requirement in proliferating cells (1, 2). As a result, many fundamental questions 
about OGT biology remain undefined, and the development of new strategies to 
explore OGT regulation and function is of great importance. 
In order to study the significance of the TPR domains in OGT’s substrate 
recognition, it would be useful to develop a system in which endogenous OGT 
can be completely replaced with exogenously expressed mutant OGT constructs. 
Ideally, OGT constructs that contain different N-terminal TPR truncations would 
be expressed in a knockout background. The different enzymatic activities of 
these mutants would then be evaluated by identifying the proteins that are 
modified by each mutant. Thus by comparing the O-GlcNAc modified proteome 
between these mutants, we would begin to uncover the role of each TPR domain 
in the recognition of specific OGT substrates. This study could be further 
extended to explore other interesting regulatory sites on OGT such as 
phosphorylation, and to evaluate changes in catalytic activity or substrate 
specificity resulting from perturbations of regulatory sites. 
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To develop a model system in which to study OGT, we took advantage of 
a floxed OGT mouse line that was previously developed (3). These mice have 
the first exon of OGT flanked with loxP sites, which result in excision of the first 
exon upon CRE recombinase expression (4, 5). Thus, isolation of cells from 
these mice and subsequent treatment of the dissociated cultures with CRE 
expressing lentivirus would allow for the efficient knockout of OGT. With a 
knockout OGT cell system in hand, we could then express mutant forms of OGT 
to study the effects of specific domains or PTM’s of OGT.  
Previously, adenovirus was used to express OGT in cardiomyocytes (6, 
7), HeLa cells (2), and HepG2 cells (8). Although adenovirus has been 
successfully used in many contexts for efficient transfection of primary cells (9-
12), it presented challenges to generating OGT mutant constructs that we wished 
to study. Most importantly, the generation of adenovirus requires several cloning 
steps with the use of shuttle vectors. As we anticipated the need to produce 
many mutant forms of OGT to investigate the roles of various TPR domains or 
post-translational modifications (such as serine to alanine mutants, or serine to 
aspartate or glutamate), we sought a system that would not require extensive 
cloning to create each mutant. Furthermore, adenovirus represented a more 
significant threat for infecting humans, and serious precautions would need to be 
taken to prevent infections. We turned our attention to the use of lentiviral 
vectors, which use a single plasmid that can be mutagenized in one step to 
facilitate the creation of many mutants. 
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Lentivirus has been used extensively to transfect many different cell types 
efficiently and with low cytotoxicity (13). This strategy for cellular transfection is 
especially useful for difficult-to-transfect cell lines such as primary cells and post-
mitotic cells such as neurons. Commonly used lentiviral vectors are replication-
deficient, which increases their safety tremendously, as they are not able to 
replicate without the exogenous addition of replication genes in trans (14). 
Lentiviral vectors have a finite capacity for RNA cargo, although virus has been 
made successfully with cargo over 18 kb in length (15). Despite this large upper 
maximum, viral titers decrease semi-logarithmically with increasing vector length, 
and generating high-titer lentivirus with vectors over 7.5 kb is very challenging in 
practice (16). Beyond the size of the vector, lentivirus infectivity can be optimized 
by including a polypurine tract in the transfer vector, harvesting virus at earlier 
time points, collection in serum-free media, and concentration by 
ultracentrifugation (17). Thus, although there are size restrictions to lentivirus-
mediated transfection, it represents the best option for efficient transfection of 
neurons. 
A.2 Results 
A.2.1 Developing a cellular OGT knockout system 
We sought to develop an OGT knockout system, to understand the role of 
the TPR repeats in OGT substrate specificity. Our initial strategy focused on 
knocking down OGT in human embryonic kidney (HEK293T) cells, because of 
their overall robust nature. These cells are easily transfected, and thus mutant 
OGT protein could easily be expressed in this cell type after efficient knockdown. 
123 
 
Previous work in the lab produced a transient OGT knockdown 293T line (OGTkd 
293T), which had ~90% knockdown of OGT (Figure 4.1A). This was 
accomplished by transfecting cells with an shRNA construct that targeted 
endogenous OGT. Although OGT protein levels were substantially reduced in 
these cells, global O-GlcNAc levels remained significant (Figure 4.1B), as 
monitored by a chemoenzymatic method that allows visualization of O-GlcNAc 
modified proteins by fluorescence (18). Thus, background O-GlcNAc levels were 
simply too high for this system to be useful. 
We then turned our attention to our mouse line that carries a floxed OGT 
genotype. Transfecting these neurons with CRE recombinase produces true 
OGT knockout cells, and previous work in the lab showed that these neurons 
remain viable for weeks. We characterized the time course of OGT knockout in 
neurons after the addition of CRE recombinase. As shown in Figure 4.2, 
complete knockout occurs by 10DIV after the addition of CRE recombinase. Two 
different OGT antibodies, DM17 and AL28, confirmed loss of OGT protein, and 
anti-O-GlcNAc antibody RL2 demonstrated loss of O-GlcNAcylated proteins.  
In order to efficiently transfect neurons, we attempted to generate OGT 
expressing lentivirus. Previous attempts in the lab were unable to generate 
infectious OGT lentivirus, even though production of other lentiviruses expressing 
proteins such as a CRE was successful. In order to understand why OGT 
lentivirus was not successful, we generated a catalytic dead form of OGT 
(D925A) in a lentiviral construct, and were successfully able to infect 293T cells  
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Figure 4.1: Generation of 293T 
cell line with OGT knockdown 
does not stably maintain low O-
GlcNAc levels. (A) 293T cells 
stably transfected with OGT shRNA 
show significant reduction in OGT 
protein levels; however, (B) 
labeling of lysates with the 
chemoenzymatic approach shows 
that lysates retain significant levels 
of O-GlcNAcylated proteins. 
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Figure 4.2: OGT knockout with CRE virus in floxed OGT 
neurons occurs by day 10. Cortical neurons from floxed OGT 
mice were isolated and treated with either Cherry control or CRE 
cherry lentivirus. Two different OGT antibodies (DM17, AL28) 
were used to evaluate OGT protein levels, and shows almost 
complete loss of OGT protein by 10DIV. Anti-O-GlcNAc antibody 
RL2 shows loss of O-GlcNAcylated proteins by 10DIV. 
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(Figure 4.3A). This result suggested that OGT activity during lentivirus generation 
may contribute to our inability to generate infectious OGT virus.  
In an attempt to limit the effects of OGT expression during lentiviral 
packaging, we transfected virus producing cells with the packaging proteins first, 
in the absence of the OGT containing lentiviral construct. This was done to allow 
the packaging proteins to be expressed in the cells before OGT overexpression. 
Then after 12 hours, the OGT containing lentiviral construct was transfected into 
the same cells (Figure 4.3B). Some virus was made, and although at very low 
titer, was able to transfect both 293T cells and a few neurons (Figure 4.3C, D). 
By optimizing the timing of transfections, it may be possible to produce higher 
titer virus with this strategy. This was not immediately pursued, because the 
observed titer was very low.  
With the knowledge that OGT catalytic activity was likely repressing virus 
production, we attempted to develop a strategy to temporarily turn off OGT 
expression during virus production. We decided to use a CRE-loxP system to 
introduce a translational stop codon before the OGT gene, which could be 
excised upon the addition of CRE recombinase (Figure 4.4A).  
In this way, the translation of OGT would be off during virus production, 
but after the virus was produced and used to infect neurons, CRE recombinase 
could be added to excise the stop codon and allow for OGT expression. A 
lentiviral construct containing a floxed stop cassette in front of the OGT gene was 
generated, and it successfully produced virus (Figure 4.4B). Unfortunately, the 
floxed stop cassette was not efficiently excised from the plasmid by CRE  
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Figure 4.3: Towards generating infectious OGT lentivirus. (A) 
Successful packaging and transduction of 293T cells with catalytic dead 
OGT (D925A) suggests that OGT activity during lentivirus packaging 
inhibits lentivirus production. (B) Strategy to produce lentivirus by allowing 
viral proteins to be expressed before addition of OGT containing plasmid. 
(C, D) Wild-type OGT virus successfully transfecting 293T cells and 
neurons. Unfortunately titers were extremely low. 
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Figure 4.4: Using a floxed stop casette to 
eliminate OGT expression during virus 
production . (A) Schematic of floxed stop 
cassette construct used to turn off OGT 
expression during virus packaging. OGT is 
only expressed if CRE recombinase is 
present to remove the stop cassette. (B) 
Virus is successfully made from the construct 
in (A), and infects 293T cells. (C) However, 
upon the addition of a CRE expressing 
plasmid, no FLAG tagged OGT is expressed, 
suggesting a problem with the floxed stop 
cassette. (D) To avoid possible complications 
with a stop cassette that is too short to 
mediate recombination, GFP was inserted 
between the loxP sites. It was efficiently 
removed upon addition of CRE, and a 
species corresponding to FLAG-OGT 
appeared as well. Unfortunately, this 
construct never made infectious virus, 
possibly due to the increased size of the new 
construct.  
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recombinase, as no flag-tagged OGT was observed after addition of CRE (Figure 
4.4C). We hypothesized that there were not enough intervening base pairs 
between the two loxP sites to efficiently create the secondary Holliday junction 
structure necessary. Although it was reported that a minimum of 90 base pairs 
was required and our stop cassette contained 100 intervening base pairs, the 
excision did not take place.  
Typically, commercially available floxed stop cassettes contain several 
hundred intervening base pairs, but this was initially avoided because our 
lentiviral construct was already large and viral titer is known to drop significantly 
with increased construct size (19). As the small cassette did not work, we then 
attempted to create a construct with a larger intervening sequence. We 
generated a construct that contained a floxed GFP with stop codon in front of the 
OGT gene. When this construct was transiently transfected with or without CRE 
in 293T cells, we observed the desired products, as visualized by FLAG western 
analysis (Figure 4.4D), indicating that the stop cassette was efficiently removed 
by CRE. Unfortunately, this construct did not produce infectious virus, and we 
suspect this is due to the extra size that the floxed GFP adds to the construct, 
making it too large.   
  We also attempted to generate OGT virus by expressing OGT behind a 
neuronal-specific promoter. We reasoned that if the OGT gene was driven by a 
neuronal-specific promoter, it would not be expressed in virus producing cells 
(293FT) and thus expression of virus packaging proteins would not be inhibited. 
We obtained synapsin and calcium/calmodulin-dependent kinase II (αCamKII) 
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promoter lentivirus constructs from Dr. Rusty Lansford (Caltech). During initial 
characterization, these empty virus constructs expressing only GFP efficiently 
made virus and infected neurons. Unfortunately, we observed GFP expression in 
our 293FT virus production cells, meaning that these cells must have active 
transcription of synapsin and αCamKII promoter-regulated genes. This was quite 
unexpected, but a review of the literature revealed a study that suggested that 
293T cells had many characteristics of immature neurons, including expression 
of neurofilaments L, M and H (12). 
A.3 Discussion  
The main challenge to generating an OGT knockout cell line is that it is 
required for cellular proliferation. As a result, efforts to knockdown OGT in 293T 
cells proved futile, because when colonies that contained greater than 80% 
knockdown were isolated, after a few passages these cells gradually increased 
OGT levels. This is believed to occur because OGT expression provides a 
tremendous growth advantage and thus cells that express more OGT are 
selected for after each passage. Even in experiments containing cells with over 
80% knockdown, O-GlcNAc levels seemed to be similar to wild-type cells, and it 
appears that even 10% of normal OGT protein levels are sufficient to maintain O-
GlcNAc levels. In order to study the effects of OGT mutations or TPR truncations, 
a clean background would be needed. As complete knockout is not possible for 
dividing cells, we turned our attention to post-mitotic neurons.  
Floxed OGT mice provide a source of neurons and fibroblasts that have 
the potential to become OGT knockout. We concentrated on neurons, as they 
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are post-mitotic and may be less susceptible to toxicity associated with loss of 
OGT. Cortical neurons were isolated from E15 embryos and were treated with 
CRE recombinase expressing lentivirus to knock out OGT. Complete loss of 
OGT protein was show to occur by 10DIV after virus addition, and anti-O-GlcNAc 
antibody showed a loss of O-GlcNAc signal by 10DIV as well. This represents a 
novel strategy to study the effects of OGT loss, which is not normally possible in 
dividing cells. 
 Although this system provides a potential source of OGT knockout cells, 
several challenges needed to be addressed before we could utilize this system 
experimentally. The largest challenge with using neurons is that they are 
resistant to most forms of transfection. Typical calcium phosphate or liposomal 
mediated transfection techniques produce at best 10% transfection efficiencies, 
and are toxic to the cells. Electroporation of neurons results in transfection 
efficiencies approaching 30%, but causes extensive cell death (~50%). We 
sought a transfection technique that would yield high efficiencies, and low cell 
toxicity. This led us to a lentivirus mediated transfection system, which has been 
used in many instances to transfect neurons at greater than 95% efficiencies with 
little cell toxicity (19).  
Despite our best efforts, initial attempts to generate OGT lentivirus were 
unsuccessful. We were able to make high titer lentivirus for CRE recombinase 
and mCherry, and so we evaluated the differences between the constructs. The 
only difference was the identity and size of the gene cargo being delivered. Thus, 
we suspected that inefficiencies in virus generation may be due to the transient 
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overexpression of OGT during viral production. It has been shown that O-GlcNAc 
modification of the transcription factor SP1 suppresses its activity, which is 
necessary for expression of lentiviral packaging proteins in certain instances 
(20). Although SP1 does not regulate the expression of the lentiviral packaging 
proteins in our system, it is possible that the significant increase in OGT 
expression during virus production has a similar inhibitory effect on the 
expression of these proteins, especially in light of the fact that O-GlcNAc 
modification has been identified on many proteins that regulate transcription and 
translation (21). In order to test this hypothesis, we generated a catalytic dead 
form of OGT and showed that it was packaged into lentivirus, suggesting that 
OGT activity during virus production was indeed inhibiting infectious virus 
production. We attempted to circumvent this issue by transfecting viral packaging 
proteins 12 hours before OGT construct transfection, to give the viral proteins a 
‘head start’ in the absence of OGT overexpression. This produced some 
infectious virus that was able to transfect 293T cells and a few neurons, but at 
incredibly low titers. Optimization of the timing if transfection of each lentiviral 
construct may improve titers, and should be explored in the future.  
Finally, in an attempt to completely turn off OGT expression during virus 
packaging, a floxed stop cassette was used to introduce a stop codon before the 
OGT gene, which could be removed upon the addition of CRE recombinase. This 
construct successfully made OGT virus, but we were unable to remove the stop 
codon with CRE recombinase. We suspected that this was due to the small 
distance between the two loxP sites (100bp), and so we introduced a GFP in 
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front of the stop codon. 293T cells transiently transfected with this construct was 
shown to only express OGT after the addition of CRE recombinase expressing 
plasmid. Unfortunately, this construct never made infectious virus, and we 
propose that the additional 700bp from the GFP inserted may have increased the 
lentivirus construct to a size that was too large to be incorporated into a virus 
capsid efficiently. Importantly, cloning lentiviral constructs suffered from frequent 
unproductive recombination of plasmids and new cloning strategies may facilitate 
the development of new lentiviral constructs. 
A.4 Conclusion 
Here we have generated and characterized a neuronal OGT knockout 
system where efficient knockout of OGT occurs in 10 days and provides a source 
of OGT-null cells for future studies. Although our initial attempts to produce OGT 
virus have failed, it remains an important goal because efficient transfection of 
neurons with OGT mutants would provide us with a strategy to characterize the 
function of the TPR repeats and other OGT mutants.  
Future work will aim to make our floxed GFP construct smaller to facilitate 
virus production. It may also be possible to find a promoter that expresses in 
neurons but not in 293T cells, as this would also prevent OGT overexpression 
during virus production.  A tetracycline-inducible OGT could also be used to limit 
OGT expression in 293T cells, although a fetal bovine serum (FBS) substitute 
may be necessary as most FBS contain tetracycline. Finally, development of a 
FLAG-tagged OGT mouse with Cas9 technology is currently being explored in 
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the lab, and OGT mutants of interest could be introduced into endogenous loci 
with this technology, in cell lines if not in mice. 
 
A.5 Methods 
A.5.1 Production of 293T OGT knockdown cells 
OGT shRNA constructs were made as described by manufacturer’s 
protocol (Addgene) and transfected into 293T cells with Lipofectamine 2000 
(Invitrogen) using manufacturer’s protocol. Cells were then plated at a low 
density and single colonies were picked, and tested for OGT knockdown. 
Western analysis was performed as described in Chapter 2, with DM-17 anti-
OGT antibody (Sigma). 
A.5.2 Chemoenzymatic labeling with GalT 
Cells were lysed as described in Chapter 2 in 2% SDS with protease 
inhibitors, and 200ug of protein was precipitated and labeled at 1 mg/mL as per 
the Click-It™ O-GlcNAc Enzymatic Labeling System instructions (Invitrogen). 
Briefly, precipitated samples were dissolved to 5 mg/mL in 1% SDS, 20 mM 
HEPES, pH 7.9 and diluted 5-fold into a buffer with the following final 
concentrations: 20 mM HEPES, pH 7.9, 50 mM NaCl, 2% NP-40, 5.5 mM MnCl2. 
UDP-GalNAz 1 (25 μM), and GalT (25 ng/μL) were added, and the samples were 
incubated at 4 °C for 14-20 h. The samples were subsequently labeled with the 
TAMRA-alkyne dye 3 as per the Click-It™ TAMRA Glycoprotein Detection Kit 
instructions (Invitrogen). Samples were then loaded onto Bis-Tris gels and 
visualized with a Typhoon imager. 
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A.5.3 Lentiviral constructs 
pLEMPRA-FLAG-OGT: OGT shRNA lentivirus vector was constructed by 
inserting into the pLLX vector (Zhou Neuron 2006) an OGT shRNA DNA hairpin 
directed against the sequence 5’- GCCTGACAATACTGGTGTT -3’. pLEMPRA 
FLAG-OGT vector was constructed by removing the MeCP2 sequence and 
shRNA cassettes from the pLEMPRA-MeCP2 vector (Zhou Neuron 2006) and 
cloning in the OGT shRNA cassette (from the pLLX vector) and the rat OGT 
sequence subcloned from pcDNA3.1/HisC-HA3-OGT (a kind gift from Dr. Jeffrey 
E. Kudlow). To make the pLEMPRA-FLAG-OGT sequence resistant to the 
shRNA, the five silent mutations were introduced into the CREB sequence 
indicated in lower case letters: 5’AAGAgCCtGAcAAtACtGGT3’. The different 
mutants of OGT were created using QuikChange Lightning site-directed 
mutagenesis kits. The resulting pLEMPRA-FLAGOGT construct expresses 
FLAG-OGT following an EGFP-IRES sequence. pLenti-PGK-iCRE-mCherry and 
pLenti-PGK-iCRE-T2a-mCherry: iCRE-nls from pBOB-CAG-iCRE-SD (Addgene 
plasmid 12336) was subcloned into a pLenti- PGK-H2B-mCherry vector (a kind 
gift from Dr. Rusty Lansford, California Institute of Technology) after first 
removing the H2B sequence. The iCRE was positioned N-terminus to and in-
frame with the mCherry to generate a fusion protein. To produce separated CRE 
and mCherry proteins, pLenti-PGK-iCRE-T2a-mCherry was also generated. 
CRE-T2a-mCherry was produced by introducing the T2a with GSG linker 
sequence (GSGEGRGSLLTCGDVEENPGP) into the Xba1 site between the 
iCRE and mCherry sequence elements of pLenti-PGK-iCRE-cherry. pLEMPRA-
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FLAG-floxed stop cassette-OGT: loxP sites were introduced to a PCR product 
with primers to amplify either a region of 100bp with multiple stop codons in 
many frames (floxed stop cassette) or a GFP with a stop codon at the end. This 
insert was cloned behind the FLAG tag and in front of the OGT of pLEMPRA-
FLAG-OGT, using an EcoR1 site. pLenti Syn and CamKII constructs were a gift 
from Dr. Rusty Lansford, Caltech. 
A.5.4 Production of lentivirus 
 Lentivirus was generated using the Invitrogen Virapower kit and 
corresponding protocol with some modification. 293TF cells were seeded onto 
tissue culture plates that had been fresh coated with 0.1% gelatin A (Sigma), and 
grown in DMEM with 10% FBS. At 60% confluence, cells were washed 1x with 
sterile PBS (Ca/Mg-free) and media was replaced with 5 ml of DMEM media with 
no additives. At this time, cells were transfected with the lentivirus packaging 
plasmids pLp1, pLp2, VSV-G and lentivirus vector (1:1:1:1 by weight) according 
to the Lipofectamine2000 (Invitrogen) instructions but with only half the 
recommended total DNA used per transfection. After 6h incubation, the cell 
media was replaced with Complete DMEM solution (DMEM high glucose, 10% 
FBS, 1 mM Na pyruvate, 1 % nonessential amino acids (GIBCO 1140), penicillin 
(100 U ml-1), streptomycin (100 mg ml-1, 10 mM Hepes). From this point on, 
media was collected and replaced every 12 hours for 3 days, filtered through a 
0.8 μm syringe filter, tested, and stored frozen at -20 °C. 
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